{ "version": "2.2", "instance": { "inpha-20251231.htm": { "nsprefix": "inpha", "nsuri": "http://www.innate-pharma.com/20251231", "dts": { "inline": { "local": [ "inpha-20251231.htm" ] }, "schema": { "local": [ "inpha-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "inpha-20251231_cal.xml" ] }, "definitionLink": { "local": [ "inpha-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "inpha-20251231_lab.xml" ] }, "presentationLink": { "local": [ "inpha-20251231_pre.xml" ] } }, "keyStandard": 297, "keyCustom": 241, "axisStandard": 30, "axisCustom": 2, "memberStandard": 39, "memberCustom": 176, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2025": 4, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1 }, "contextCount": 1194, "entityCount": 1, "segmentCount": 221, "elementCount": 1018, "unitCount": 26, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 2782, "http://xbrl.sec.gov/dei/2025": 52, "http://xbrl.sec.gov/cyd/2025": 15, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://www.innate-pharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.innate-pharma.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "longName": "9952151 - Statement - Consolidated Statements of Financial Position", "shortName": "Consolidated Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:OtherNoncurrentNonfinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R4": { "role": "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "longName": "9952152 - Statement - Consolidated Statements of Income (Loss)", "shortName": "Consolidated Statements of Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R5": { "role": "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "9952153 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R6": { "role": "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows", "longName": "9952154 - Statement - Consolidated Statement of Cash Flows", "shortName": "Consolidated Statement of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R7": { "role": "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical", "longName": "9952155 - Statement - Consolidated Statement of Cash Flows - Parenthetical", "shortName": "Consolidated Statement of Cash Flows - Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestPaidClassifiedAsOperatingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestPaidClassifiedAsOperatingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "longName": "9952156 - Statement - Consolidated Statement of Changes in Shareholders' Equity", "shortName": "Consolidated Statement of Changes in Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-12", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.innate-pharma.com/role/Thecompany", "longName": "9952157 - Disclosure - The company", "shortName": "The company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCompanySignificantContractsAndKeyEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCompanySignificantContractsAndKeyEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.innate-pharma.com/role/Accountingpoliciesandstatementofcompliance", "longName": "9952158 - Disclosure - Accounting policies and statement of compliance", "shortName": "Accounting policies and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.innate-pharma.com/role/Managementoffinancialrisksandfairvalue", "longName": "9952159 - Disclosure - Management of financial risks and fair value", "shortName": "Management of financial risks and fair value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.innate-pharma.com/role/Cashcashequivalentsandfinancialassets", "longName": "9952160 - Disclosure - Cash, cash equivalents and financial assets", "shortName": "Cash, cash equivalents and financial assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.innate-pharma.com/role/Tradereceivablesandothers", "longName": "9952161 - Disclosure - Trade receivables and others", "shortName": "Trade receivables and others", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.innate-pharma.com/role/Intangibleassets", "longName": "9952162 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.innate-pharma.com/role/Propertyandequipment", "longName": "9952163 - Disclosure - Property and equipment", "shortName": "Property and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.innate-pharma.com/role/Tradepayablesandothers", "longName": "9952164 - Disclosure - Trade payables and others", "shortName": "Trade payables and others", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.innate-pharma.com/role/Financialliabilities", "longName": "9952165 - Disclosure - Financial liabilities", "shortName": "Financial liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.innate-pharma.com/role/Employeebenefits", "longName": "9952166 - Disclosure - Employee benefits", "shortName": "Employee benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.innate-pharma.com/role/Sharecapitalandsharebasedpayments", "longName": "9952167 - Disclosure - Share capital and share based payments", "shortName": "Share capital and share based payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement", "longName": "9952168 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement", "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.innate-pharma.com/role/Revenueandgovernmentfinancingforresearchexpenditures", "longName": "9952169 - Disclosure - Revenue and government financing for research expenditures", "shortName": "Revenue and government financing for research expenditures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.innate-pharma.com/role/Operatingexpenses", "longName": "9952170 - Disclosure - Operating expenses", "shortName": "Operating expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.innate-pharma.com/role/Netfinancialincomeloss", "longName": "9952171 - Disclosure - Net financial income (loss)", "shortName": "Net financial income (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.innate-pharma.com/role/IncomeTax", "longName": "9952172 - Disclosure - Income Tax", "shortName": "Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigations", "longName": "9952173 - Disclosure - Commitments, contingencies and litigations", "shortName": "Commitments, contingencies and litigations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.innate-pharma.com/role/Relatedpartytransactions", "longName": "9952174 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.innate-pharma.com/role/Incomelosspershare", "longName": "9952175 - Disclosure - Income (loss) per share", "shortName": "Income (loss) per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.innate-pharma.com/role/Eventsafterthereportingdate", "longName": "9952176 - Disclosure - Events after the reporting date", "shortName": "Events after the reporting date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies", "longName": "9955511 - Disclosure - Accounting policies and statement of compliance (Policies)", "shortName": "Accounting policies and statement of compliance (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DescriptionOfAccountingPolicyForBasisOfPreparationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DescriptionOfAccountingPolicyForBasisOfPreparationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.innate-pharma.com/role/ThecompanyTables", "longName": "9955512 - Disclosure - The company (Tables)", "shortName": "The company (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceTables", "longName": "9955513 - Disclosure - Accounting policies and statement of compliance (Tables)", "shortName": "Accounting policies and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsTables", "longName": "9955514 - Disclosure - Cash, cash equivalents and financial assets (Tables)", "shortName": "Cash, cash equivalents and financial assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.innate-pharma.com/role/TradereceivablesandothersTables", "longName": "9955515 - Disclosure - Trade receivables and others (Tables)", "shortName": "Trade receivables and others (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.innate-pharma.com/role/IntangibleassetsTables", "longName": "9955516 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.innate-pharma.com/role/PropertyandequipmentTables", "longName": "9955517 - Disclosure - Property and equipment (Tables)", "shortName": "Property and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.innate-pharma.com/role/TradepayablesandothersTables", "longName": "9955518 - Disclosure - Trade payables and others (Tables)", "shortName": "Trade payables and others (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesTables", "longName": "9955519 - Disclosure - Financial liabilities (Tables)", "shortName": "Financial liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.innate-pharma.com/role/EmployeebenefitsTables", "longName": "9955520 - Disclosure - Employee benefits (Tables)", "shortName": "Employee benefits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsTables", "longName": "9955521 - Disclosure - Share capital and share based payments (Tables)", "shortName": "Share capital and share based payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R42": { "role": "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables", "longName": "9955522 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)", "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresTables", "longName": "9955523 - Disclosure - Revenue and government financing for research expenditures (Tables)", "shortName": "Revenue and government financing for research expenditures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.innate-pharma.com/role/OperatingexpensesTables", "longName": "9955524 - Disclosure - Operating expenses (Tables)", "shortName": "Operating expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.innate-pharma.com/role/NetfinancialincomelossTables", "longName": "9955525 - Disclosure - Net financial income (loss) (Tables)", "shortName": "Net financial income (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.innate-pharma.com/role/IncomeTaxTables", "longName": "9955526 - Disclosure - Income Tax (Tables)", "shortName": "Income Tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsTables", "longName": "9955527 - Disclosure - Related party transactions (Tables)", "shortName": "Related party transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.innate-pharma.com/role/IncomelosspershareTables", "longName": "9955528 - Disclosure - Income (loss) per share (Tables)", "shortName": "Income (loss) per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.innate-pharma.com/role/ThecompanyAdditionalInformationDetails", "longName": "9955529 - Disclosure - The company - Additional Information (Details)", "shortName": "The company - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "inpha:NumberOfTherapeuticApproaches", "unitRef": "approach", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "inpha:NumberOfTherapeuticApproaches", "unitRef": "approach", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails", "longName": "9955530 - Disclosure - The company - 2014 Novo Nordisk A/S monalizumab agreement (Details)", "shortName": "The company - 2014 Novo Nordisk A/S monalizumab agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-57", "name": "inpha:SharesIssuedForTheAcquisitionOfC5aRIntangibleAssetInShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R51": { "role": "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "longName": "9955531 - Disclosure - The company - 2015 AstraZeneca monalizumab agreements (Details)", "shortName": "The company - 2015 AstraZeneca monalizumab agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-62", "name": "inpha:ReceiptsFromCodevelopmentAgreementAndOptionAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-62", "name": "inpha:ReceiptsFromCodevelopmentAgreementAndOptionAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "longName": "9955532 - Disclosure - The company - Agreement related to IPH5201 with AstraZeneca (Details)", "shortName": "The company - Agreement related to IPH5201 with AstraZeneca (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "inpha:ReceiptsFromCodevelopmentAgreementAndOptionAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R53": { "role": "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails", "longName": "9955533 - Disclosure - The company - Agreement related to additional preclinical molecules with AstraZeneca (Details)", "shortName": "The company - Agreement related to additional preclinical molecules with AstraZeneca (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-76", "name": "inpha:NumberOfPreclinicalMolecules", "unitRef": "preclinicalmolecule", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "inpha:RevenueFromContractsWithCustomersAdvancePaymentReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R54": { "role": "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails", "longName": "9955534 - Disclosure - The company - Agreements related to avdoralimab with Novo Nordisk and with AstraZeneca (Details)", "shortName": "The company - Agreements related to avdoralimab with Novo Nordisk and with AstraZeneca (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-78", "name": "inpha:UpfrontPayment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-78", "name": "inpha:UpfrontPayment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails", "longName": "9955535 - Disclosure - The company - Collaboration and license agreements concluded with Sanofi for the development of \"NK Cell engages\" in oncology (Details)", "shortName": "The company - Collaboration and license agreements concluded with Sanofi for the development of \"NK Cell engages\" in oncology (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-76", "name": "inpha:NumberOfPreclinicalMolecules", "unitRef": "preclinicalmolecule", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "inpha:NumberOfSpecifiedTargets", "unitRef": "target_option", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R56": { "role": "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails", "longName": "9955536 - Disclosure - The company - Key events (Details)", "shortName": "The company - Key events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-95", "name": "inpha:NumberOfPatientsPlannedToBeEnrolledInMedicalStudy", "unitRef": "clinicalproductcandidate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "inpha:ExpectedDecreaseInNumberOfEmployeesPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R57": { "role": "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails", "longName": "9955537 - Disclosure - The Company - Summary of the company's shareholding information (Details)", "shortName": "The Company - Summary of the company's shareholding information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-101", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-101", "name": "inpha:NumberOfVotingRightsHeld", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R58": { "role": "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "longName": "9955538 - Disclosure - Accounting policies and statement of compliance - Additional Information (Details)", "shortName": "Accounting policies and statement of compliance - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DefinedContributionPlanContributionPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DefinedContributionPlanContributionPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofEffectofChangesinForeignExchangeRatesDetails", "longName": "9955539 - Disclosure - Accounting policies and statement of compliance - Disclosure of Effect of Changes in Foreign Exchange Rates (Details)", "shortName": "Accounting policies and statement of compliance - Disclosure of Effect of Changes in Foreign Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "usdPerEUR", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "usdPerEUR", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails", "longName": "9955540 - Disclosure - Accounting policies and statement of compliance - Disclosure of Depreciation Periods (Details)", "shortName": "Accounting policies and statement of compliance - Disclosure of Depreciation Periods (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-122", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfDepreciationPeriodsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfDepreciationPeriodsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails", "longName": "9955541 - Disclosure - Management of financial risks and fair value (Details)", "shortName": "Management of financial risks and fair value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "inpha:CashCashEquivalentsAndShortTermInvestmentsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:PercentageOfRevenueDenominatedInUSDollars", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R62": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails", "longName": "9955542 - Disclosure - Cash, cash equivalents and financial assets - Disclosure of Cash, Cash Equivalents and Financial Assets (Details)", "shortName": "Cash, cash equivalents and financial assets - Disclosure of Cash, Cash Equivalents and Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsAdditionalInformationDetails", "longName": "9955543 - Disclosure - Cash, cash equivalents and financial assets - Additional Information (Details)", "shortName": "Cash, cash equivalents and financial assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "inpha:TotalCashCashEquivalentsAndFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-133", "name": "inpha:TotalCashCashEquivalentsAndFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R64": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails", "longName": "9955544 - Disclosure - Cash, cash equivalents and financial assets - Disclosure of Reconciliation of Changes in Loss Allowance and Explanation of Changes in Gross Carrying Amount for Financial Instruments (Details)", "shortName": "Cash, cash equivalents and financial assets - Disclosure of Reconciliation of Changes in Loss Allowance and Explanation of Changes in Gross Carrying Amount for Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:CurrentInvestments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ifrs-full:CurrentInvestments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R65": { "role": "http://www.innate-pharma.com/role/TradereceivablesandothersDetails", "longName": "9955545 - Disclosure - Trade receivables and others (Details)", "shortName": "Trade receivables and others (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:OtherCurrentReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:OtherCurrentReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails", "longName": "9955546 - Disclosure - Intangible assets - Disclosure of Detailed Information about Intangible Assets (Details)", "shortName": "Intangible assets - Disclosure of Detailed Information about Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R67": { "role": "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "longName": "9955547 - Disclosure - Intangible assets - Additional Information (Details)", "shortName": "Intangible assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R68": { "role": "http://www.innate-pharma.com/role/PropertyandequipmentDetails", "longName": "9955548 - Disclosure - Property and equipment (Details)", "shortName": "Property and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R69": { "role": "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "longName": "9955549 - Disclosure - Trade payables and others (Details)", "shortName": "Trade payables and others (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "longName": "9955550 - Disclosure - Financial liabilities - Disclosure of Financial Liabilities Per Maturity (Details)", "shortName": "Financial liabilities - Disclosure of Financial Liabilities Per Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:FinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:ProceedsFromLeaseLiabilitiesAndOtherNonCashEffectsClassifiedAsFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R71": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "longName": "9955551 - Disclosure - Financial liabilities - Additional Information (Details)", "shortName": "Financial liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:WriteOffOfARightOfUseAsset", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R72": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails", "longName": "9955552 - Disclosure - Financial liabilities - Disclosure of Schedule for the Contractual Flows of Financial Liabilities (Details)", "shortName": "Financial liabilities - Disclosure of Schedule for the Contractual Flows of Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-287", "name": "ifrs-full:CurrentFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfFinancialLiabilitiesClassifiedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R73": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "longName": "9955553 - Disclosure - Financial liabilities - Disclosure of Maturity Analysis for Non-Derivative Financial Liabilities (Details)", "shortName": "Financial liabilities - Disclosure of Maturity Analysis for Non-Derivative Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:BankBorrowingsUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:BankBorrowingsUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails", "longName": "9955554 - Disclosure - Employee benefits - Disclosure of defined benefit plans (Details)", "shortName": "Employee benefits - Disclosure of defined benefit plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-397", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R75": { "role": "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "longName": "9955555 - Disclosure - Employee benefits - Additional Information (Details)", "shortName": "Employee benefits - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-401", "name": "inpha:OtherLongTermBenefitsYearsOfServiceThresholdTwo", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:IncreaseDecreaseInEmployeeBenefitObligationPer25BasisPointChangesInDiscountRate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R76": { "role": "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "longName": "9955556 - Disclosure - Employee benefits - Disclosure of Actuarial Assumptions for Defined Benefit Plans (Details)", "shortName": "Employee benefits - Disclosure of Actuarial Assumptions for Defined Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-397", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfActuarialAssumptionsForDefinedBenefitPlansTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-397", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfActuarialAssumptionsForDefinedBenefitPlansTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails", "longName": "9955557 - Disclosure - Employee benefits - Disclosure of Net Defined Benefit Liability (Asset) (Details)", "shortName": "Employee benefits - Disclosure of Net Defined Benefit Liability (Asset) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R78": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "longName": "9955558 - Disclosure - Share capital and share based payments - Additional Information (Details)", "shortName": "Share capital and share based payments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:IssuedCapital", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R79": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "longName": "9955559 - Disclosure - Share capital and share based payments - Disclosure of Changes in Share Capital (Details)", "shortName": "Share capital and share based payments - Disclosure of Changes in Share Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-506", "name": "ifrs-full:ParValuePerShare", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R80": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "longName": "9955560 - Disclosure - Share capital and share based payments - Disclosure of Number and Weighted Average Exercise Prices of Other Equity Instruments (Details)", "shortName": "Share capital and share based payments - Disclosure of Number and Weighted Average Exercise Prices of Other Equity Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-856", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-856", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails", "longName": "9955561 - Disclosure - Share capital and share based payments - Disclosure of Terms and Conditions of Other Equity Instruments (Details)", "shortName": "Share capital and share based payments - Disclosure of Terms and Conditions of Other Equity Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-858", "name": "inpha:VestingPeriodOtherEquityInstrumentsGranted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-858", "name": "inpha:NontransferabilityPeriodOtherEquityInstrumentsGranted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R82": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "longName": "9955562 - Disclosure - Share capital and share based payments - Disclosure of Changes in Number of Other Equity Instruments Outstanding (Details)", "shortName": "Share capital and share based payments - Disclosure of Changes in Number of Other Equity Instruments Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-901", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "inpha:DisclosureOfChangeInNumberOfOtherEquityInstrumentsOutstandingTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-904", "name": "ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "inpha:DisclosureOfChangeInNumberOfOtherEquityInstrumentsOutstandingTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R83": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "longName": "9955563 - Disclosure - Share capital and share based payments - Disclosure of Closing Balance of Share-Based Payment Arrangements (Details)", "shortName": "Share capital and share based payments - Disclosure of Closing Balance of Share-Based Payment Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-905", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "inpha:DisclosureOfChangeInNumberOfOtherEquityInstrumentsOutstandingTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-907", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfClosingBalanceOfShareBasedPaymentArrangementsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R84": { "role": "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "longName": "9955564 - Disclosure - Share capital and share based payments - Disclosure of Breakdown of Expenses per Financial Year (Details)", "shortName": "Share capital and share based payments - Disclosure of Breakdown of Expenses per Financial Year (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-809", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R85": { "role": "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails", "longName": "9955565 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement (Details)", "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "longName": "9955566 - Disclosure - Revenue and government financing for research expenditures - Additional Information (Details)", "shortName": "Revenue and government financing for research expenditures - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1091", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R87": { "role": "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "longName": "9955567 - Disclosure - Revenue and government financing for research expenditures - Disclosure of Revenue from Collaboration and Licensing Agreements (Details)", "shortName": "Revenue and government financing for research expenditures - Disclosure of Revenue from Collaboration and Licensing Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1063", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R88": { "role": "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "longName": "9955568 - Disclosure - Revenue and government financing for research expenditures - Disclosure of Changes in Deferred Revenue and Collaboration Liabilities (Details)", "shortName": "Revenue and government financing for research expenditures - Disclosure of Changes in Deferred Revenue and Collaboration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-1142", "name": "ifrs-full:ContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfVarianceOfDeferredRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1098", "name": "ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R89": { "role": "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails", "longName": "9955569 - Disclosure - Revenue and government financing for research expenditures - Disclosure of Variance of Deferred Revenue (Details)", "shortName": "Revenue and government financing for research expenditures - Disclosure of Variance of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1149", "name": "inpha:IncreaseThroughUpfrontPaymentContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfVarianceOfDeferredRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R90": { "role": "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofGovernmentFinancingforResearchExpendituresDetails", "longName": "9955570 - Disclosure - Revenue and government financing for research expenditures - Disclosure of Government Financing for Research Expenditures (Details)", "shortName": "Revenue and government financing for research expenditures - Disclosure of Government Financing for Research Expenditures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "inpha:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails", "longName": "9955571 - Disclosure - Operating expenses - Disclosure of Expenses by Nature (Details)", "shortName": "Operating expenses - Disclosure of Expenses by Nature (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "inpha:SubcontractingCosts", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:SubcontractingCosts", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails", "longName": "9955572 - Disclosure - Operating expenses - Disclosure of Audit and Non-Audit Fees (Details)", "shortName": "Operating expenses - Disclosure of Audit and Non-Audit Fees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AuditorsRemunerationForAuditServices", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfAuditAndNonAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AuditorsRemunerationForAuditServices", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfAuditAndNonAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.innate-pharma.com/role/OperatingexpensesAdditionalInformationDetails", "longName": "9955573 - Disclosure - Operating expenses - Additional Information (Details)", "shortName": "Operating expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ShorttermEmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ifrs-full:NumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R94": { "role": "http://www.innate-pharma.com/role/NetfinancialincomelossDetails", "longName": "9955574 - Disclosure - Net financial income (loss) (Details)", "shortName": "Net financial income (loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "inpha:InterestsAndGainsOnFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:InterestsAndGainsOnFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails", "longName": "9955575 - Disclosure - Income Tax - Disclosure of Deferred Assets and Liabilities (Details)", "shortName": "Income Tax - Disclosure of Deferred Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-4", "name": "inpha:DeferredTaxAssetsOffsetAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "inpha:DeferredTaxAssetsOffsetAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.innate-pharma.com/role/IncomeTaxAdditionalInformationDetails", "longName": "9955576 - Disclosure - Income Tax - Additional Information (Details)", "shortName": "Income Tax - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-4", "name": "inpha:UnusedTaxLossesWithNoExpirationDate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "inpha:UnusedTaxLossesWithNoExpirationDate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails", "longName": "9955577 - Disclosure - Income Tax - Disclosure of Tax Rate Reconciliation (Details)", "shortName": "Income Tax - Disclosure of Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AccountingProfit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTaxRateReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AccountingProfit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTaxRateReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "longName": "9955578 - Disclosure - Commitments, contingencies and litigations (Details)", "shortName": "Commitments, contingencies and litigations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-4", "name": "inpha:NonCancellableOffBalanceSheetPurchasedCommitments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "inpha:NonCancellableOffBalanceSheetPurchasedCommitments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails", "longName": "9955579 - Disclosure - Related party transactions - Disclosure of Key Management Personnel Compensation (Details)", "shortName": "Related party transactions - Disclosure of Key Management Personnel Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails", "longName": "9955580 - Disclosure - Related party transactions - Additional Information (Details)", "shortName": "Related party transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-4", "name": "inpha:NumberOfMembersOfTheSupervisoryBoardNotAppointedToTheBoardOfDirectors", "unitRef": "supervisoryboard", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "inpha:NumberOfMembersOfTheSupervisoryBoardNotAppointedToTheBoardOfDirectors", "unitRef": "supervisoryboard", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails", "longName": "9955581 - Disclosure - Related party transactions - Disclosure of Transactions Between Related Parties (Details)", "shortName": "Related party transactions - Disclosure of Transactions Between Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CashAdvancesAndLoansFromRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:CashAdvancesAndLoansFromRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.innate-pharma.com/role/IncomelosspershareSummaryofIncomeLossperShareDetails", "longName": "9955582 - Disclosure - Income (loss) per share - Summary of Income (Loss) per Share (Details)", "shortName": "Income (loss) per share - Summary of Income (Loss) per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "unique": true } }, "R103": { "role": "http://www.innate-pharma.com/role/IncomelosspershareAdditionalInformationDetails", "longName": "9955583 - Disclosure - Income (loss) per share - Additional Information (Details)", "shortName": "Income (loss) per share - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-1", "name": "inpha:NumberOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:NumberOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20251231.htm", "first": true, "unique": true } } }, "tag": { "inpha_A2014NovoNordiskASMonalizumabAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2014NovoNordiskASMonalizumabAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2014 Novo Nordisk A/S monalizumab agreement", "label": "2014 Novo Nordisk A/S Monalizumab Agreement [Member]", "documentation": "This member stands for 2014 Novo Nordisk A/S monalizumab agreement." } } }, "auth_ref": [] }, "inpha_A2015AstraZenecaMonalizumabAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2015AstraZenecaMonalizumabAgreementsMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015 monalizumab agreement, with AstraZeneca", "label": "2015 AstraZeneca Monalizumab Agreements [Member]", "documentation": "This member stands for 2015 AstraZeneca monalizumab agreements." } } }, "auth_ref": [] }, "inpha_A2016FreePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2016FreePreferredSharesMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 free preferred shares", "label": "2016 Free Preferred Shares [Member]", "documentation": "Related to the 2016 free preferred shares." } } }, "auth_ref": [] }, "inpha_A2016PreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2016PreferredSharesMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 Preferred shares", "label": "2016 Preferred Shares [Member]", "documentation": "2016 Preferred Shares" } } }, "auth_ref": [] }, "inpha_A2017AvdoralimabInLicensingAgreementWithNovoNordiskASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2017AvdoralimabInLicensingAgreementWithNovoNordiskASMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Avdoralimab In-Licensing Agreement With Novo Nordisk A/S", "label": "2017 Avdoralimab In-Licensing Agreement With Novo Nordisk A/S [Member]", "documentation": "2017 Avdoralimab In-Licensing Agreement With Novo Nordisk A/S" } } }, "auth_ref": [] }, "inpha_A2017FreePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2017FreePreferredSharesMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 free preferred shares", "label": "2017 Free Preferred Shares [Member]", "documentation": "Related to the 2017 free preferred shares." } } }, "auth_ref": [] }, "inpha_A2017PreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2017PreferredSharesMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Preferred shares", "label": "2017 Preferred Shares [Member]", "documentation": "2017 Preferred Shares" } } }, "auth_ref": [] }, "inpha_A2018AvdoralimabAstraZenecaAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "A2018AvdoralimabAstraZenecaAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 Avdoralimab AstraZeneca Agreement", "label": "2018 Avdoralimab AstraZeneca Agreement [Member]", "documentation": "2018 Avdoralimab AstraZeneca Agreement" } } }, "auth_ref": [] }, "inpha_AGABonus2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus2017Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2017", "label": "AGA Bonus 2017 [Member]", "documentation": "This member stands for AGA Bonus 2017." } } }, "auth_ref": [] }, "inpha_AGABonus20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus20181Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2018-1", "label": "AGA Bonus 2018-1 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGABonus2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus2018Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2018", "label": "AGA Bonus 2018 [Member]", "documentation": "This member stands for AGA Bonus 2018." } } }, "auth_ref": [] }, "inpha_AGABonus20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus20191Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2019-1", "label": "AGA Bonus 2019-1 [Member]", "documentation": "Related to AGA bonus 2019-1." } } }, "auth_ref": [] }, "inpha_AGABonus202012Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus202012Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2020-1 & 2", "label": "AGA Bonus 2020-1 & 2 [Member]", "documentation": "AGA Bonus 2020-1 & 2" } } }, "auth_ref": [] }, "inpha_AGABonus20201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus20201Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2020-1", "label": "AGA Bonus 2020 -1 [Member]", "documentation": "AGA Bonus 2020 -1" } } }, "auth_ref": [] }, "inpha_AGABonus2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus2020Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2020", "label": "AGA Bonus 2020 [Member]", "documentation": "AGA Bonus 2020" } } }, "auth_ref": [] }, "inpha_AGABonus20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus20211Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2021-1", "label": "AGA Bonus 2021-1 [Member]", "documentation": "AGA Bonus 2021-1" } } }, "auth_ref": [] }, "inpha_AGABonus20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus20221Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2022-1 [Member]", "label": "AGA Bonus 2022-1 [Member]", "documentation": "AGA Bonus 2022-1" } } }, "auth_ref": [] }, "inpha_AGABonus20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGABonus20231Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA New Members 2023-1", "label": "AGA Bonus 2023-1 [Member]", "documentation": "AGA Bonus 2023-1" } } }, "auth_ref": [] }, "inpha_AGAEmployee2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployee2025Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employee 2025", "label": "AGA Employee 2025 [Member]", "documentation": "AGA Employee 2025" } } }, "auth_ref": [] }, "inpha_AGAEmployees20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployees20161Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employees 2016-1", "label": "AGA Employees 2016-1 [Member]", "documentation": "This member stands for AGA Employees 2016-1." } } }, "auth_ref": [] }, "inpha_AGAEmployees20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployees20162Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employees 2016-2", "label": "AGA Employees 2016-2 [Member]", "documentation": "This member stands for AGA Employees 2016-2." } } }, "auth_ref": [] }, "inpha_AGAEmployees2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployees2017Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employee 2017", "label": "AGA Employees 2017 [Member]", "documentation": "This member stands for AGA Employees 2017." } } }, "auth_ref": [] }, "inpha_AGAEmployees2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployees2018Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employees 2018", "label": "AGA Employees 2018 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAEmployees20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployees20241Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA employees 2024-1", "label": "AGA Employees 2024-1 [Member]", "documentation": "AGA Employees 2024-1" } } }, "auth_ref": [] }, "inpha_AGAEmployees202501Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployees202501Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA employees 2025-01", "label": "AGA Employees 2025-01 [Member]", "documentation": "AGA Employees 2025-01" } } }, "auth_ref": [] }, "inpha_AGAEmployees20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAEmployees20251Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employees 2025-1", "label": "AGA Employees 2025-1 [Member]", "documentation": "AGA Employees 2025-1" } } }, "auth_ref": [] }, "inpha_AGAManagement20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAManagement20161Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Management 2016-1", "label": "AGA Management 2016-1 [Member]", "documentation": "This member stands for AGA Management 2016-1." } } }, "auth_ref": [] }, "inpha_AGAManagement20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAManagement20162Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Management 2016-2", "label": "AGA Management 2016-2 [Member]", "documentation": "This member stands for AGA Management 2016-2." } } }, "auth_ref": [] }, "inpha_AGAManagement20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAManagement20241Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Management 2024-1", "label": "AGA Management 2024-1 [Member]", "documentation": "AGA Management 2024-1" } } }, "auth_ref": [] }, "inpha_AGAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA", "label": "AGA [Member]", "documentation": "This member stands for AGA." } } }, "auth_ref": [] }, "inpha_AGANewMembers20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGANewMembers20171Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA New Members 2017-1", "label": "AGA New Members 2017-1 [Member]", "documentation": "This member stands for AGA New Members 2017-1." } } }, "auth_ref": [] }, "inpha_AGANewMembers20231ManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGANewMembers20231ManagementMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA New Members 2023-1", "verboseLabel": "AGA New Members 2023-1 Management", "label": "AGA New Members 2023-1 Management [Member]", "documentation": "AGA New Members 2023-1 Management" } } }, "auth_ref": [] }, "inpha_AGANewMembers20241ManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGANewMembers20241ManagementMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA New Members 2024-1", "verboseLabel": "AGA New Members 2024 - 1 Management", "label": "AGA New Members 2024-1 Management [Member]", "documentation": "AGA New Members 2024-1 Management" } } }, "auth_ref": [] }, "inpha_AGAP20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAP20162Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP 2016-2", "label": "AGAP 2016-2 [Member]", "documentation": "This member stands for AGAP 2016-2." } } }, "auth_ref": [] }, "inpha_AGAP2019Employees2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAP2019Employees2019Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP 2019 Employees 2019", "label": "AGAP 2019 Employees 2019 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAP2019Management2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAP2019Management2019Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP 2019 Management 2019", "label": "AGAP 2019 Management 2019 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAPEmployee2020AGAPManagement2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployee2020AGAPManagement2020Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employee 2020 / AGAP Management 2020", "label": "AGAP Employee 2020 / AGAP Management 2020 [Member]", "documentation": "AGAP Employee 2020 / AGAP Management 2020" } } }, "auth_ref": [] }, "inpha_AGAPEmployee2021AGAPManagement2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployee2021AGAPManagement2021Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employee 2021 / AGAP Management 2021", "label": "AGAP Employee 2021 / AGAP Management 2021 [Member]", "documentation": "AGAP Employee 2021 / AGAP Management 2021" } } }, "auth_ref": [] }, "inpha_AGAPEmployee2022AGAPManagement2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployee2022AGAPManagement2022Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employee 2022 / AGAP Management 2022", "label": "AGAP Employee 2022 / AGAP Management 2022 [Member]", "documentation": "AGAP Employee 2022 / AGAP Management 2022" } } }, "auth_ref": [] }, "inpha_AGAPEmployee2023AGAPManagement2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployee2023AGAPManagement2023Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employee 2023/ AGAP Management 2023", "label": "AGAP Employee 2023 / AGAP Management 2023 [Member]", "documentation": "AGAP Employee 2023-1 / AGAP Management 2023" } } }, "auth_ref": [] }, "inpha_AGAPEmployee2024AGAPManagement2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployee2024AGAPManagement2024Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employee 2024/ AGAP Management 2024", "label": "AGAP Employee 2024/ AGAP Management 2024 [Member]", "documentation": "AGAP Employee 2024/ AGAP Management 2024" } } }, "auth_ref": [] }, "inpha_AGAPEmployees20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployees20161Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employees 2016-1", "label": "AGAP Employees 2016-1 [Member]", "documentation": "This member stands for AGAP Employees 2016-1." } } }, "auth_ref": [] }, "inpha_AGAPEmployees20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployees20171Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employees 2017-1", "label": "AGAP Employees 2017-1 [Member]", "documentation": "Related to a plan." } } }, "auth_ref": [] }, "inpha_AGAPEmployees2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPEmployees2017Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employees 2017-1", "label": "AGAP Employees 2017 [Member]", "documentation": "This member stands for AGAP Employees 2017." } } }, "auth_ref": [] }, "inpha_AGAPManagement20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPManagement20161Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2016-1", "label": "AGAP Management 2016-1 [Member]", "documentation": "This member stands for AGAP Management 2016-1." } } }, "auth_ref": [] }, "inpha_AGAPManagement20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPManagement20162Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2016-2", "label": "AGAP Management 2016-2 [Member]", "documentation": "This member stands for AGAP Management 2016-2." } } }, "auth_ref": [] }, "inpha_AGAPManagement20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPManagement20171Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2017-1", "label": "AGAP Management 2017-1 [Member]", "documentation": "Related to a plan." } } }, "auth_ref": [] }, "inpha_AGAPManagement2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPManagement2017Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2017", "label": "AGAP Management 2017 [Member]", "documentation": "This member stands for AGAP Management 2017." } } }, "auth_ref": [] }, "inpha_AGAPPerfEmployees20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPPerfEmployees20181Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Perf Employees 2018-1", "label": "AGAP Perf Employees 2018-1 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAPPerfManagement20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPPerfManagement20181Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Perf Management 2018-1", "label": "AGAP Perf Management 2018-1 [Member]", "documentation": "This member stands for AGA Perf Management 2018-1." } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees2018Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2018", "label": "AGA Perf Employees 2018 [Member]", "documentation": "This member stands for AGA Perf Employees 2018." } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees20191Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2019-1", "label": "AGA Perf Employees 2019-1 [Member]", "documentation": "AGA Perf Employees 2019-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees2019AGAPerfManagement2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees2019AGAPerfManagement2019Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2019 / AGA Perf Management 2019 [Member]", "label": "AGA Perf Employees 2019 / AGA Perf Management 2019 [Member]", "documentation": "Related to stock plans." } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees2019Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2019", "label": "AGA Perf Employees 2019 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20201AGAPerfManagement2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees20201AGAPerfManagement2020Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2020-1 / AGA Perf Management 2020", "label": "AGA Perf Employees 2020-1 / AGA Perf Management 2020 [Member]", "documentation": "AGA Perf Employees 2020-1 / AGA Perf Management 2020" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees20201Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2020-1", "label": "AGA Perf Employees 2020-1 [Member]", "documentation": "AGA Perf Employees 2020-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees20211Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2021-1", "label": "AGA Perf Employees 2021-1 [Member]", "documentation": "AGA Perf Employees 2021-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees20221Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2022-1", "label": "AGA Perf Employees 2022-1 [Member]", "documentation": "AGA Perf Employees 2022-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees20231Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2023-1", "label": "AGA Perf Employees 2023-1 [Member]", "documentation": "AGA Perf Employees 2023-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfEmployees20241Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2024-1", "label": "AGA Perf Employees 2024-1 [Member]", "documentation": "AGA Perf Employees 2024-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement2018Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2018", "label": "AGA Perf Management 2018 [Member]", "documentation": "This member stands for AGA Perf Management 2018." } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement20191Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2019-1", "label": "AGA Perf Management 2019-1 [Member]", "documentation": "AGA Perf Management 2019-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement2019Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2019", "label": "AGA Perf Management 2019 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement20201Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2020-1", "label": "AGA Perf Management 2020-1 [Member]", "documentation": "AGA Perf Management 2020-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement20211Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2021-1", "label": "AGA Perf Management 2021-1 [Member]", "documentation": "AGA Perf Management 2021-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement20221Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2022-1", "label": "AGA Perf Management 2022-1 [Member]", "documentation": "AGA Perf Management 2022-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement20231Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2023-1", "label": "AGA Perf Management 2023-1 [Member]", "documentation": "AGA Perf Management 2023-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement20241Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2024-1", "verboseLabel": "AGA Perf Management 2024-1", "label": "AGA Perf Management 2024-1 [Member]", "documentation": "AGA Perf Management 2024-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPerfManagement20242Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2024-2", "label": "AGA Perf Management 2024-2 [Member]", "documentation": "AGA Perf Management 2024-2" } } }, "auth_ref": [] }, "inpha_AGAPlanEpargneEntreprise2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPlanEpargneEntreprise2022Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA \"Plan Epargne Entreprise\" 2022", "label": "AGA \"Plan Epargne Entreprise\" 2022 [Member]", "documentation": "AGA \"Plan Epargne Entreprise\" 2022" } } }, "auth_ref": [] }, "inpha_AGAPlanEpargneEntreprise2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPlanEpargneEntreprise2023Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA \"Plan Epargne Entreprise\" 2023", "verboseLabel": "AGA \"Plan Epargne Entreprise\" 2023", "label": "AGA \"Plan Epargne Entreprise\" 2023 [Member]", "documentation": "AGA \"Plan Epargne Entreprise\" 2023" } } }, "auth_ref": [] }, "inpha_AGAPlanEpargneEntreprise2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AGAPlanEpargneEntreprise2024Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA \"Plan Epargne Entreprise\" 2024", "verboseLabel": "AGA \"Plan Epargne Entreprise\" 2024", "label": "AGA \"Plan Epargne Entreprise\" 2024 [Member]", "documentation": "AGA \"Plan Epargne Entreprise\" 2024" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income (loss) before tax", "label": "Accounting profit" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r2", "r3", "r152", "r153" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Acquisitions through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r37", "r174" ] }, "inpha_ActuarialAssumptionOfAnnualMobilityRate": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualMobilityRate", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual mobility rate", "label": "Actuarial Assumption of Annual Mobility Rate", "documentation": "The amount of annual mobility rate of actuarial assumptions." } } }, "auth_ref": [] }, "inpha_ActuarialAssumptionOfAnnualTurnoverRateByAge1624Years": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualTurnoverRateByAge1624Years", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "16-24 years", "label": "Actuarial Assumption Of Annual Turnover Rate By Age 16-24 Years", "documentation": "The annual turnover rate for 16-24 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation." } } }, "auth_ref": [] }, "inpha_ActuarialAssumptionOfAnnualTurnoverRateByAge2529Years": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualTurnoverRateByAge2529Years", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "25-29 years", "label": "Actuarial Assumption Of Annual Turnover Rate By Age 25-29 Years", "documentation": "The annual turnover rate for 25-29 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation." } } }, "auth_ref": [] }, "inpha_ActuarialAssumptionOfAnnualTurnoverRateByAge3034Years": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualTurnoverRateByAge3034Years", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "30-34 years", "label": "Actuarial Assumption Of Annual Turnover Rate By Age 30-34 Years", "documentation": "The annual turnover rate for 30-34 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation." } } }, "auth_ref": [] }, "inpha_ActuarialAssumptionOfAnnualTurnoverRateByAge3539Years": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualTurnoverRateByAge3539Years", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "35-39 years", "label": "Actuarial Assumption Of Annual Turnover Rate By Age 35-39 Years", "documentation": "The annual turnover rate for 35-39 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation." } } }, "auth_ref": [] }, "inpha_ActuarialAssumptionOfAnnualTurnoverRateByAge4044Years": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualTurnoverRateByAge4044Years", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "40-44 years", "label": "Actuarial Assumption Of Annual Turnover Rate By Age 40-44 Years", "documentation": "The annual turnover rate for 40-44 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation." } } }, "auth_ref": [] }, "inpha_ActuarialAssumptionOfAnnualTurnoverRateByAge4549Years": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualTurnoverRateByAge4549Years", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "45-49 years", "label": "Actuarial Assumption Of Annual Turnover Rate By Age 45-49 Years", "documentation": "The annual turnover rate for 45-49 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation." } } }, "auth_ref": [] }, "inpha_ActuarialAssumptionOfAnnualTurnoverRateByAgeOver50Years": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfAnnualTurnoverRateByAgeOver50Years", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "+50 years", "label": "Actuarial Assumption Of Annual Turnover Rate By Age Over 50 Years", "documentation": "The annual turnover rate for employees over 50 years old used as a significant actuarial assumption to determine the present value of a defined benefit obligation." } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of discount rates", "verboseLabel": "Discount rate (iBoxx Corporate AA) for retirement", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r408" ] }, "inpha_ActuarialAssumptionOfEmployeeContributions": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfEmployeeContributions", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of wages costs", "label": "Actuarial Assumption of Employee Contributions", "documentation": "The amount of rate of wages costs in actuarial assumptions." } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of expected rates of salary increases", "verboseLabel": "Annual rate of increase in wages", "label": "Actuarial assumption of expected rates of salary increases" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r408" ] }, "inpha_ActuarialAssumptionOfRateOfContributions": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ActuarialAssumptionOfRateOfContributions", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of contributions", "label": "Actuarial Assumption of Rate Of Contributions", "documentation": "The percent of rate of contributions for actuarial assumptions." } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfRetirementAge2019", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of retirement age", "verboseLabel": "Age at retirement", "label": "Actuarial assumption of retirement age" } }, "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r408" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r339" ] }, "inpha_AdditionalMilestonesPaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AdditionalMilestonesPaymentReceivable", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional milestones payment receivable", "label": "Additional Milestones Payment Receivable", "documentation": "Additional Milestones Payment Receivable" } } }, "auth_ref": [] }, "inpha_AdditionalMilestonesPaymentReceivableNotEligible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AdditionalMilestonesPaymentReceivableNotEligible", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional milestones payment, not eligible", "label": "Additional Milestones Payment Receivable, Not Eligible", "documentation": "Additional Milestones Payment Receivable, Not Eligible" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions considerations", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r37", "r174" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Additions other than through business combinations, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r405" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r352" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r352" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r352" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accrued interests on financial assets", "label": "Adjustments for decrease (increase) in accrued income including contract assets" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in accrued income including contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Accrued income including contract assets; Profit (loss)]" } } }, "auth_ref": [ "r418" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_IncreaseDecreaseInWorkingCapitalBeforeAdjustments", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others (excluding rebates related to capital expenditures), variance", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r420" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization, net", "label": "Adjustments for depreciation and amortisation expense" } } }, "auth_ref": [ "r419" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of financial assets", "label": "Adjustments for fair value losses (gains)" } } }, "auth_ref": [ "r419" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gains (losses) on assets and other financial assets", "label": "Adjustments for finance income" } } }, "auth_ref": [ "r420" ] }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposal of property and equipment (scrapping)", "label": "Adjustments for gain (loss) on disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } } }, "auth_ref": [ "r420" ] }, "inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AdjustmentsForIncreaseDecreaseInCollaborationLiabilities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_IncreaseDecreaseInWorkingCapitalBeforeAdjustments", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities - current and non-current portion, variance", "label": "Adjustments For Increase (Decrease) In Collaboration Liabilities", "documentation": "Adjustments for increase (decrease) in collaboration liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_IncreaseDecreaseInWorkingCapitalBeforeAdjustments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue - current and non-current portion, variance", "label": "Adjustments for increase (decrease) in deferred income including contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r418" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits costs", "label": "Adjustments for increase (decrease) in employee benefit liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r420" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_IncreaseDecreaseInWorkingCapitalBeforeAdjustments", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others (excluding payables related to capital expenditures), variance", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r420" ] }, "inpha_AdjustmentsForIncreaseDecreaseTaxCreditRetentionsCIR": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AdjustmentsForIncreaseDecreaseTaxCreditRetentionsCIR", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "5% retained - Tax credit refund, variance", "label": "Adjustments For Increase (Decrease), Tax Credit Retentions, CIR", "documentation": "Adjustments For Increase (Decrease), Tax Credit Retentions, CIR" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in provisions", "label": "Adjustments for provisions" } } }, "auth_ref": [ "r419" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of the net income (loss) and the cash generated from (used for) the operating activities", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r419" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange (gains) losses on financial assets", "label": "Adjustments for unrealised foreign exchange losses (gains)" } } }, "auth_ref": [ "r258", "r419" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r397" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r310", "r321", "r331", "r364" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r313", "r324", "r334", "r367" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r398" ] }, "inpha_AgreementRelatedToANKETIPH62WithSanofiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementRelatedToANKETIPH62WithSanofiMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program", "label": "Agreement Related To ANKET IPH62 With Sanofi [Member]", "documentation": "Agreement Related To ANKET IPH62 With Sanofi" } } }, "auth_ref": [] }, "inpha_AgreementRelatedToANKETIPH67WithSanofiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementRelatedToANKETIPH67WithSanofiMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to the progress of related research program", "label": "Agreement Related To ANKET IPH67 With Sanofi [Member]", "documentation": "Agreement Related To ANKET IPH67 With Sanofi" } } }, "auth_ref": [] }, "inpha_AgreementRelatedToAdditionalPreclinicalMoleculesWithAstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementRelatedToAdditionalPreclinicalMoleculesWithAstraZenecaMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement related to additional preclinical molecules with AstraZeneca", "label": "Agreement Related To Additional Preclinical Molecules With AstraZeneca [Member]", "documentation": "This member stands for agreement related to additional preclinical molecules with AstraZeneca." } } }, "auth_ref": [] }, "inpha_AgreementRelatedToIPH5201WithAstraZenecaInitialPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementRelatedToIPH5201WithAstraZenecaInitialPaymentMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPH5201 agreement, with AstraZeneca, initial payment", "label": "Agreement Related To IPH5201 With AstraZeneca, Initial Payment [Member]", "documentation": "Agreement Related To IPH5201 With AstraZeneca, Initial Payment" } } }, "auth_ref": [] }, "inpha_AgreementRelatedToIPH5201WithAstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementRelatedToIPH5201WithAstraZenecaMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPH5201 agreement, with AstraZeneca", "verboseLabel": "of which IPH5201 agreement - AstraZeneca", "label": "Agreement Related To IPH5201 With AstraZeneca [Member]", "documentation": "This member stands for Agreement related to IPH5201 with AstraZeneca." } } }, "auth_ref": [] }, "inpha_AgreementRelatedToIPH5201WithAstraZenecaMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementRelatedToIPH5201WithAstraZenecaMilestonePaymentMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPH5201 agreement, with AstraZeneca, milestone payment", "label": "Agreement Related To IPH5201 With AstraZeneca, Milestone Payment [Member]", "documentation": "Agreement Related To IPH5201 With AstraZeneca, Milestone Payment" } } }, "auth_ref": [] }, "inpha_AgreementRelatedToIPH6101WithSanofiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementRelatedToIPH6101WithSanofiMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPH6101 agreement, with Sanofi", "verboseLabel": "of which Sanofi agreement 2016", "label": "Agreement Related To IPH6101 With Sanofi [Member]", "documentation": "Agreement Related To IPH6101 With Sanofi" } } }, "auth_ref": [] }, "inpha_AgreementWithTakedaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementWithTakedaMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "of which Takeda agreement 2023", "label": "Agreement With Takeda [Member]", "documentation": "Agreement With Takeda" } } }, "auth_ref": [] }, "inpha_AgreementWithTakedaOnResearchOfAntibodyDrugConjugatesADCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementWithTakedaOnResearchOfAntibodyDrugConjugatesADCMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement with Takeda on research of Antibody Drug Conjugates (ADC)", "label": "Agreement With Takeda on Research of Antibody Drug Conjugates (ADC) [Member]", "documentation": "Agreement With Takeda on Research of Antibody Drug Conjugates (ADC)" } } }, "auth_ref": [] }, "inpha_AgreementsWithGenzymeForNKCellEngagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementsWithGenzymeForNKCellEngagesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements with Genzyme for NK Cell engages", "label": "Agreements with Genzyme for NK Cell engages [Member]", "documentation": "Agreements with Genzyme for NK Cell engages" } } }, "auth_ref": [] }, "inpha_AgreementsWithSanofiForNKCellEngagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AgreementsWithSanofiForNKCellEngagesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements with Sanofi for NK Cell engages", "label": "Agreements with Sanofi for NK Cell engages [Member]", "documentation": "Agreements with Sanofi for NK Cell engages" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r352" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r359" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r314", "r325", "r335", "r359", "r368", "r372", "r380" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r378" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "inpha_AmericanDepositorySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AmericanDepositorySharesMember", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "American Depository Shares", "label": "American Depository Shares [Member]", "documentation": "American Depository Shares" } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation", "label": "Amortisation, intangible assets other than goodwill" } } }, "auth_ref": [ "r41", "r178" ] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails": { "parentTag": "inpha_NetAmountsReceivablePayableRelatedPartyTransactions", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Liabilities", "label": "Amounts payable, related party transactions" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r22", "r25", "r166" ] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails": { "parentTag": "inpha_NetAmountsReceivablePayableRelatedPartyTransactions", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Receivables", "label": "Amounts receivable, related party transactions" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r22", "r25", "r166" ] }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AnalysisOfIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Analysis of income and expense [abstract]", "label": "Analysis of income and expense [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Statutory tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r3", "r153" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r72", "r73", "r74", "r120", "r123", "r195", "r196", "r221" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r425", "r429" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function", "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r425", "r429" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r293", "r294", "r317" ] }, "inpha_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Auditor Information [Abstract]", "label": "Auditor Information [Abstract]", "documentation": "Auditor Information" } } }, "auth_ref": [] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLineItems", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor [Line Items]", "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r293", "r294", "r317" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r293", "r294", "r317" ] }, "inpha_AuditorRemunerationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AuditorRemunerationTable", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Remuneration [Table]", "label": "Auditor Remuneration [Table]", "documentation": "Auditor Remuneration" } } }, "auth_ref": [] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorTable", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor [Table]", "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ifrs-full_AuditorsRemuneration": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemuneration", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Auditor's remuneration" } } }, "auth_ref": [ "r429" ] }, "ifrs-full_AuditorsRemunerationForAuditServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForAuditServices", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails": { "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Audit fees", "label": "Auditor's remuneration for audit services" } } }, "auth_ref": [ "r429" ] }, "ifrs-full_AuditorsRemunerationForOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForOtherServices", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails": { "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-audit fees (services other than the audit of financial statements)", "label": "Auditor's remuneration for other services" } } }, "auth_ref": [ "r429" ] }, "inpha_AuditorsRemunerationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AuditorsRemunerationLineItems", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Auditors Remuneration [Line Items]", "label": "Auditors Remuneration [Line Items]", "documentation": "Auditors Remuneration" } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Effective tax rate", "label": "Average effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r153" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofEffectofChangesinForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Average rate (\u20ac1 equals to USD)", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r429" ] }, "inpha_AverageLifeOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "AverageLifeOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average life of BSA", "label": "Average Life Other Equity Instruments Granted", "documentation": "The average life of other equity instruments granted." } } }, "auth_ref": [] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average number of employees", "label": "Average number of employees" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r429" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r375" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r376" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r371" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r371" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r371" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r371" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r371" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r371" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r374" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r373" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r372" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r372" ] }, "inpha_BSA20112Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA20112Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2011-2", "label": "BSA 2011-2 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_BSA2013Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA2013Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2013", "label": "BSA 2013 [Member]", "documentation": "This member stands for BSA 2013." } } }, "auth_ref": [] }, "inpha_BSA2014Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA2014Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2014", "label": "BSA 2014 [Member]", "documentation": "This member stands for BSA 2014." } } }, "auth_ref": [] }, "inpha_BSA20151Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA20151Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-1", "label": "BSA 2015-1 [Member]", "documentation": "This member stands for BSA 2015-1." } } }, "auth_ref": [] }, "inpha_BSA20152Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA20152Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-2", "label": "BSA 2015-2 [Member]", "documentation": "This member stands for BSA 2015-2." } } }, "auth_ref": [] }, "inpha_BSA2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA2017Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2017", "label": "BSA 2017 [Member]", "documentation": "This member stands for BSA 2017." } } }, "auth_ref": [] }, "inpha_BSA20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA20221Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2022-1", "label": "BSA 2022-1 [Member]", "documentation": "BSA 2022-1" } } }, "auth_ref": [] }, "inpha_BSA20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA20231Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2023-1", "label": "BSA 2023-1 [Member]", "documentation": "BSA 2023-1" } } }, "auth_ref": [] }, "inpha_BSA20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSA20251Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2025-1", "label": "BSA-2025-1 [Member]", "documentation": "BSA-2025-1" } } }, "auth_ref": [] }, "inpha_BSAAR2011Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSAAR2011Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR 2011", "label": "BSAAR 2011 [Member]", "documentation": "This member stands for BSAAR 2011." } } }, "auth_ref": [] }, "inpha_BSAAR2012Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSAAR2012Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR 2012", "label": "BSAAR 2012 [Member]", "documentation": "This member stands for BSAAR 2012." } } }, "auth_ref": [] }, "inpha_BSAAR2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSAAR2015Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR 2015", "label": "BSAAR 2015 [Member]", "documentation": "This member stands for BSAAR 2015." } } }, "auth_ref": [] }, "inpha_BSAARMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSAARMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR", "label": "BSAAR [Member]", "documentation": "This member stands for BSAAR." } } }, "auth_ref": [] }, "inpha_BSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BSAMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA", "label": "BSA [Member]", "documentation": "This member stands for BSA." } } }, "auth_ref": [] }, "ifrs-full_BankBorrowingsUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BankBorrowingsUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Undiscounted cash flows", "label": "Bank borrowings, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r271", "r275" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/IncomelosspershareSummaryofIncomeLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic income (loss) per share (in EUR per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r29", "r30" ] }, "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Basic income (loss) per share from continuing operations (in EUR per share)", "label": "Basic earnings (loss) per share from continuing operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r29", "r30" ] }, "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Basic income (loss) per share from discontinued operations (in EUR per share)", "label": "Basic earnings (loss) per share from discontinued operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]" } } }, "auth_ref": [ "r30", "r31" ] }, "inpha_BorrowingGracePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BorrowingGracePeriod", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, grace period", "label": "Borrowing, Grace Period", "documentation": "Borrowing, Grace Period" } } }, "auth_ref": [] }, "inpha_BorrowingMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BorrowingMaturity", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, maturity", "label": "Borrowing, Maturity", "documentation": "Borrowing, Maturity" } } }, "auth_ref": [] }, "inpha_BorrowingMaturityExtensionPeriodOption": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BorrowingMaturityExtensionPeriodOption", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, maturity, extension period option", "label": "Borrowing, Maturity, Extension Period Option", "documentation": "Borrowing, Maturity, Extension Period Option" } } }, "auth_ref": [] }, "inpha_BorrowingNumberOfLoanAgreement": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BorrowingNumberOfLoanAgreement", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, number of loan agreement", "label": "Borrowing, Number Of Loan Agreement", "documentation": "Borrowing, Number Of Loan Agreement" } } }, "auth_ref": [] }, "inpha_BorrowingPercentageOfStateGuaranteedLoan": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BorrowingPercentageOfStateGuaranteedLoan", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, percentage of state-guaranteed loan", "label": "Borrowing, Percentage Of State-Guaranteed Loan", "documentation": "Borrowing, Percentage Of State-Guaranteed Loan" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total borrowings", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r433" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r423" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name", "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r423" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r423" ] }, "inpha_BorrowingsMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BorrowingsMaturityPeriod", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, maturity period", "label": "Borrowings, Maturity Period", "documentation": "Borrowings, Maturity Period" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r52", "r76", "r89", "r92", "r147", "r260", "r261", "r423" ] }, "inpha_BpifranceParticipationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "BpifranceParticipationsMember", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bpifrance Participations", "label": "Bpifrance Participations [Member]", "documentation": "Bpifrance Participations" } } }, "auth_ref": [] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings\u00a0and\u00a0improvements\u00a0on buildings", "label": "Buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r404" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r294", "r317" ] }, "inpha_CIRRetentionMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CIRRetentionMaturity", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CIR retention, maturity", "label": "CIR Retention, Maturity", "documentation": "CIR Retention, Maturity" } } }, "auth_ref": [] }, "ifrs-full_CashAdvancesAndLoansFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAdvancesAndLoansFromRelatedParties", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails": { "parentTag": "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collection", "label": "Cash advances and loans from related parties" } }, "en": { "role": { "documentation": "The cash inflow from advances and loans from related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r417" ] }, "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAdvancesAndLoansMadeToRelatedParties", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails": { "parentTag": "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Cash advances and loans made to related parties" } }, "en": { "role": { "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r416" ] }, "inpha_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalent [Member]", "documentation": "This member stands for cash and cash equivalents." } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails": { "parentTag": "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails", "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows", "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at the beginning of the year", "periodEndLabel": "Cash and cash equivalents at the end of the year", "verboseLabel": "Cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r53", "r68", "r148", "r217" ] }, "inpha_CashAndCashEquivalentsAndFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CashAndCashEquivalentsAndFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents And Financial Assets [Abstract]", "documentation": "Cash And Cash Equivalents And Financial Assets" } } }, "auth_ref": [] }, "inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and financial assets denominated in US dollars", "label": "Cash, Cash Equivalents, And Financial Assets Denominated In US Dollars [Member]", "documentation": "Related to cash, cash equivalents, and financial assets denominated in US dollars." } } }, "auth_ref": [] }, "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CashCashEquivalentsAndShortTermInvestmentsAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails": { "parentTag": "inpha_TotalCashCashEquivalentsAndFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails", "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and short-term investments", "totalLabel": "Cash and cash equivalents and short-term investments", "label": "Cash, Cash Equivalents And Short-Term Investments, Assets", "documentation": "The amount of cash, cash equivalents and short-term investments." } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from / (used in) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r46", "r54" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from / (used in) investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r46", "r54" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from/ (used in) operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r46", "r54" ] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Operating cash flow before change in working capital", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r258", "r420" ] }, "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashRepaymentsOfAdvancesAndLoansFromRelatedParties", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net collection (payments)", "label": "Cash repayments of advances and loans from related parties" } }, "en": { "role": { "documentation": "The cash outflow for repayments of advances and loans from related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r417" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r112", "r189" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets", "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r112", "r189" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [axis]", "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r112", "r189" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities", "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r112", "r189" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [axis]", "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24", "r168" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for related parties", "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r24", "r168" ] }, "inpha_ChangeInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ChangeInWorkingCapital", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapitalAdjusted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Change in working capital", "label": "Change In Working Capital", "documentation": "The amount of working capital." } } }, "auth_ref": [] }, "inpha_ChangeInWorkingCapitalAdjusted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ChangeInWorkingCapitalAdjusted", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Change in working capital, adjusted", "label": "Change In Working Capital, Adjusted", "documentation": "Change In Working Capital, Adjusted" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r350" ] }, "ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CharacteristicsOfDefinedBenefitPlansAxis", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Characteristics of defined benefit plans [axis]", "label": "Characteristics of defined benefit plans [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r247" ] }, "ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CharacteristicsOfDefinedBenefitPlansDomain", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Characteristics of defined benefit plans", "label": "Characteristics of defined benefit plans [domain]" } }, "en": { "role": { "documentation": "This member stands for all defined benefit plans when disaggregated by characteristics of defined benefits plans. It also represents the standard value for the 'Characteristics of defined benefit plans' axis if no other member is used." } } }, "auth_ref": [ "r247" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r347" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r345" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r91", "r106", "r107", "r129", "r130", "r207" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets", "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r91", "r106", "r107", "r129", "r130", "r207" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r106", "r107", "r129", "r130" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities", "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r106", "r107", "r129", "r130" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r43", "r180" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [domain]", "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r43", "r180" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [axis]", "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r75", "r197" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities", "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r75", "r197" ] }, "ifrs-full_ClassesOfOtherProvisionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOtherProvisionsDomain", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [domain]", "label": "Classes of other provisions [domain]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r34", "r171" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails", "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r9", "r158" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails", "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [domain]", "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r9", "r158" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [axis]", "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r34", "r171" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r145", "r201", "r234" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital", "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r145", "r201", "r234" ] }, "inpha_ClinicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ClinicalServicesMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Services", "label": "Clinical Services [Member]", "documentation": "Clinical Services" } } }, "auth_ref": [] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofEffectofChangesinForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Closing rate (\u20ac1 equals to USD)", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r429" ] }, "inpha_CoFundPercentageOfTrialsOfLicensedProduct": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CoFundPercentageOfTrialsOfLicensedProduct", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Co-fund percentage of trials of licensed product", "label": "Co-fund Percentage Of Trials Of Licensed Product", "documentation": "The co-fund percentage of trials of licensed product." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r351" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r351" ] }, "inpha_CollaborationAndLicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CollaborationAndLicensingAgreementsMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from collaboration and licensing agreements", "label": "Collaboration And Licensing Agreements [Member]", "documentation": "This member stands for collaboration and licensing agreements." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CollaborationLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Collaboration liabilities - current and non-current portion", "label": "Collaboration Liabilities", "documentation": "The amount of collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CollaborationLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities \u2013 current portion", "label": "Collaboration Liabilities , Current", "documentation": "The amount of current collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CollaborationLiabilitiesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities", "label": "Collaboration Liabilities [Member]", "documentation": "This member stands for collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilitiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CollaborationLiabilitiesNonCurrent", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities \u2013 non-current portion", "label": "Collaboration Liabilities, Non-Current", "documentation": "The amount of non-current collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilitiesRollForwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CollaborationLiabilitiesRollForwardAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Liabilities, Roll Forward [Abstract]", "label": "Collaboration Liabilities, Roll Forward [Abstract]", "documentation": "Collaboration Liabilities, Roll Forward" } } }, "auth_ref": [] }, "inpha_CommercializationMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CommercializationMilestones", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercialization milestones", "label": "Commercialization Milestones", "documentation": "The commercialization milestones pursuant to the agreement." } } }, "auth_ref": [] }, "inpha_CommitmentsContingenciesAndLitigationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CommitmentsContingenciesAndLitigationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments, Contingencies And Litigations [Abstract]", "label": "Commitments, Contingencies And Litigations [Abstract]", "documentation": "Commitments, Contingencies And Litigations" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r356" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r355" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r357" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r354" ] }, "inpha_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Company Information [Abstract]", "label": "Company Information [Abstract]", "documentation": "Company Information" } } }, "auth_ref": [] }, "inpha_CompanyInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CompanyInformationLineItems", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company Information [Line Items]", "label": "Company Information [Line Items]", "documentation": "Company Information [Line Items]" } } }, "auth_ref": [] }, "inpha_CompanyInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CompanyInformationTable", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company Information [Table]", "label": "Company Information [Table]", "documentation": "Company Information [Table]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Elements which will be reclassified in the consolidated statement of income (loss):", "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Items which will not be reclassified in the consolidated statement of income (loss):", "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss)", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r57", "r59", "r64", "r170", "r183", "r209", "r237", "r259" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computers and IT equipment", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r404" ] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In progress", "label": "Construction in progress [member]" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r404" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract liabilities at beginning of period", "periodEndLabel": "Contract liabilities at end of period", "label": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r77", "r80", "r133" ] }, "ifrs-full_ContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Contract liabilities [abstract]" } } }, "auth_ref": [] }, "inpha_ContractLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ContractLiabilitiesMember", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities / Deferred revenue", "label": "Contract Liabilities [Member]", "documentation": "Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract", "lang": { "en-us": { "role": { "label": "Corporate information and statement of IFRS compliance [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties", "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r114" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CumulativeEffectAtDateOfInitialApplicationAxis", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative effect at date of initial application [axis]", "label": "Cumulative effect at date of initial application [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r427" ] }, "inpha_CumulativeTaxCreditRetentionsCIR": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CumulativeTaxCreditRetentionsCIR", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative 5% retained - Tax credit refund", "label": "Cumulative Tax Credit Retentions, CIR", "documentation": "Cumulative 5% Retention, CIR" } } }, "auth_ref": [] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepayments made to suppliers", "label": "Current advances to suppliers" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r429" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r60", "r225", "r259" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Current contract liabilities at beginning of period", "periodEndLabel": "Current contract liabilities at end of period", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r77" ] }, "ifrs-full_CurrentContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current contract liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue \u2013 current portion", "label": "Current deferred income including current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r433", "r436" ] }, "ifrs-full_CurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails": { "parentTag": "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails", "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "verboseLabel": "Short-term investments", "label": "Current financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities \u2013 current portion", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r98" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, current investments", "periodEndLabel": "Ending balance, current investments", "label": "Current investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r433" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r62", "r226", "r259" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "inpha_CurrentPayablesRelatedToCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CurrentPayablesRelatedToCapitalExpenditures", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Payables related to capital expenditures", "label": "Current Payables Related To Capital Expenditures", "documentation": "The amount of current payables related to capital expenditures." } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "terseLabel": "Current prepaid expenses", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r429" ] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions \u2013 current portion", "label": "Current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Income tax benefit / (expense)", "label": "Current tax expense (income) and adjustments for current tax of prior periods" } } }, "auth_ref": [ "r402" ] }, "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Trade payables and others excluding payables related to capital expenditures", "label": "Current Trade Payables And Others Excluding Payables Related To Capital Expenditures", "documentation": "The amount of current Trade payables and others, excluding payables related to capital expenditures." } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade account receivables", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r281", "r285", "r287" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "VAT refund", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r434" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r302", "r391" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r302", "r391" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r304", "r393" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r304", "r393" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r306", "r395" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r304", "r393" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r297", "r386" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r298", "r387" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r298", "r387" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r296", "r385" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r296", "r385" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r296", "r385" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r299", "r388" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r301", "r390" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r301", "r390" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r302", "r391" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r305", "r394" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r303", "r392" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r300", "r389" ] }, "inpha_DecreaseInDownPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DecreaseInDownPayment", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of borrowings, down payment", "label": "Decrease In Down Payment", "documentation": "The decrease in down payment." } } }, "auth_ref": [] }, "inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DecreaseThroughDerecognitionNonCurrentFinancialAssets", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-current financial assets, disposals", "label": "Decrease Through Derecognition Non-current Financial Assets", "documentation": "The decrease in non-current financial assets resulting from derecognition." } } }, "auth_ref": [] }, "inpha_DecreaseThroughDerecognitionShortTermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DecreaseThroughDerecognitionShortTermInvestment", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Short-term investments, disposals", "label": "Decrease Through Derecognition Short-term Investment", "documentation": "The decrease in current investment resulting from derecognition." } } }, "auth_ref": [] }, "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total, disposals", "label": "Decrease Through Derecognition Short-term Investment And Non-current Financial Assets", "documentation": "The decrease in short-term investment and non-current financial assets resulting from derecognition." } } }, "auth_ref": [] }, "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Revenue for the current financial year", "negatedTerseLabel": "Recognition in P&L", "label": "Decrease through performance obligation being satisfied, contract liabilities" } }, "en": { "role": { "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [domain]]" } } }, "auth_ref": [ "r262" ] }, "inpha_DecreaseThroughRepaymentsContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DecreaseThroughRepaymentsContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment cost to AZ", "label": "Decrease Through Repayments Contract Liabilities", "documentation": "The decrease in contract liabilities resulting from deductions." } } }, "auth_ref": [] }, "inpha_DecreaseThroughRepaymentsCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DecreaseThroughRepaymentsCurrentContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment cost to AZ", "label": "Decrease Through Repayments, Current Contract Liabilities", "documentation": "Decrease Through Repayments, Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_DecreaseThroughRepaymentsNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DecreaseThroughRepaymentsNonCurrentContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment cost to AZ", "label": "Decrease Through Repayments, Non Current Contract Liabilities", "documentation": "Decrease Through Repayments, Non Current Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredIncomeIncludingContractLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred revenue - current and non-current portion", "label": "Deferred income including contract liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r433", "r436" ] }, "inpha_DeferredRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DeferredRevenueMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities / Deferred revenue", "label": "Deferred Revenue [Member]", "documentation": "This member stands for deferred revenue." } } }, "auth_ref": [] }, "inpha_DeferredRevenueRollForwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DeferredRevenueRollForwardAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Roll Forward [Abstract]", "label": "Deferred Revenue, Roll Forward [Abstract]", "documentation": "Deferred Revenue, Roll Forward" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r4", "r154", "r220", "r222" ] }, "inpha_DeferredTaxAssetsOffsetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DeferredTaxAssetsOffsetAmount", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, offset amount", "label": "Deferred Tax Assets, Offset Amount", "documentation": "Deferred Tax Assets, Offset Amount" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax income / (loss)", "label": "Deferred tax expense (income)" } }, "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r5", "r155" ] }, "inpha_DeferredTaxLiabilitiesOffsetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DeferredTaxLiabilitiesOffsetAmount", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities, offset amount", "label": "Deferred Tax Liabilities, Offset Amount", "documentation": "Deferred Tax Liabilities, Offset Amount" } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Defined benefit obligations", "terseLabel": "Defined benefit obligation, at present value", "label": "Defined benefit obligation, at present value" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r409" ] }, "inpha_DefinedContributionPlanContributionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DefinedContributionPlanContributionPercentage", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, contribution percentage", "label": "Defined Contribution Plan Contribution Percentage", "documentation": "The contribution percentage pursuant to the defined contribution plan." } } }, "auth_ref": [] }, "inpha_DefinedContributionPlanContributionPercentageByEmployee": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DefinedContributionPlanContributionPercentageByEmployee", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, contribution percentage by employee", "label": "Defined Contribution Plan Contribution Percentage By Employee", "documentation": "The contribution percentage by employee pursuant to the defined contribution plan." } } }, "auth_ref": [] }, "inpha_DefinedContributionPlanContributionPercentageByEmployer": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DefinedContributionPlanContributionPercentageByEmployer", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, contribution percentage by employer", "label": "Defined Contribution Plan Contribution Percentage By Employer", "documentation": "The contribution percentage by employer pursuant to the defined contribution plan." } } }, "auth_ref": [] }, "inpha_DefinitiveAcquisitionOfFreeSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DefinitiveAcquisitionOfFreeSharesMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definitive acquisition of free shares", "label": "Definitive Acquisition Of Free Shares [Member]", "documentation": "Definitive Acquisition Of Free Shares" } } }, "auth_ref": [] }, "inpha_DeloitteAssociesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DeloitteAssociesMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deloitte & Associ\u00e9s", "label": "Deloitte & Associ\u00e9s [Member]", "documentation": "Deloitte & Associ\u00e9s" } } }, "auth_ref": [] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalInformationDetails", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r69", "r118", "r124", "r208", "r243", "r283" ] }, "ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation", "label": "Depreciation, property, plant and equipment including right-of-use assets" } } }, "auth_ref": [ "r405" ] }, "inpha_DescriptionOfAccountingPolicyForAccountingEstimatesAndAssumptionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForAccountingEstimatesAndAssumptionsPolicyTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Critical accounting estimates and assumptions", "label": "Description Of Accounting Policy For Accounting Estimates And Assumptions [Policy Text Block]", "documentation": "The description of the entity's accounting policy for accounting estimates and assumptions." } } }, "auth_ref": [] }, "inpha_DescriptionOfAccountingPolicyForBasisOfPreparationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationPolicyTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of preparation", "label": "Description Of Accounting Policy For Basis Of Preparation [Policy Text Block]", "documentation": "The description of the entity's accounting policy for basis of preparation." } } }, "auth_ref": [] }, "inpha_DescriptionOfAccountingPolicyForChangeInAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForChangeInAccountingPoliciesPolicyTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting policies", "label": "Description Of Accounting Policy For Change In Accounting Policies [Policy Text Block]", "documentation": "The description of accounting policy for change in accounting policies." } } }, "auth_ref": [] }, "inpha_DescriptionOfAccountingPolicyForConsolidationMethodPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForConsolidationMethodPolicyTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation method", "label": "Description Of Accounting Policy For Consolidation Method [Policy Text Block]", "documentation": "The description of the entity's accounting policy for consolidation method." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (loss) per share", "label": "Description of accounting policy for earnings per share [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Description of accounting policy for employee benefits [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Description of accounting policy for financial instruments [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Translation of transactions denominated in foreign currency", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Government financing for research expenditures", "label": "Description of accounting policy for government grants [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r17", "r164" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangibles assets, property, and equipment", "label": "Description of accounting policy for impairment of assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of assets." } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Capital", "label": "Description of accounting policy for issued capital [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r430" ] }, "inpha_DescriptionOfAccountingPolicyForNewIFRSReleasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForNewIFRSReleasesPolicyTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently issued accounting standards and interpretations", "label": "Description Of Accounting Policy For New IFRS Releases [Policy Text Block]", "documentation": "The description of the entity's accounting policy for new IFRS releases." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets held for sale and discontinued operations", "label": "Description of accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Non-current assets or disposal groups classified as held for sale]" } } }, "auth_ref": [ "r430" ] }, "inpha_DescriptionOfAccountingPolicyForOtherComprehensiveIncomePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForOtherComprehensiveIncomePolicyTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "label": "Description Of Accounting Policy For Other Comprehensive Income [Policy Text Block]", "documentation": "The description of the entity's accounting policy for other comprehensive income." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions and contingent liabilities", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Description of accounting policy for recognition of revenue [text block]" } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment information", "label": "Description of accounting policy for segment reporting [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r430" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r430" ] }, "inpha_DescriptionOfStatementOfCompliancePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DescriptionOfStatementOfCompliancePolicyTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of compliance", "label": "Description Of Statement Of Compliance [Policy Text Block]", "documentation": "The description of statement of compliance." } } }, "auth_ref": [] }, "inpha_DevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DevelopmentAndRegulatoryMilestones", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development and regulatory milestones", "label": "Development And Regulatory Milestones", "documentation": "The development and regulatory milestones pursuant to the agreement." } } }, "auth_ref": [] }, "inpha_DifferencesInTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DifferencesInTaxRates", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Differences in tax rates", "label": "Differences In Tax Rates", "documentation": "The amount of tax effect from differences in tax rates." } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/IncomelosspershareSummaryofIncomeLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted income (loss) per share (in EUR per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r29", "r30" ] }, "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted income (loss) per share from continuing operations (in EUR per share)", "label": "Diluted earnings (loss) per share from continuing operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]" } } }, "auth_ref": [ "r29", "r30" ] }, "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted income (loss) per share from discontinued operations (in EUR per share)", "label": "Diluted earnings (loss) per share from discontinued operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]" } } }, "auth_ref": [ "r30", "r31" ] }, "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareSummaryofIncomeLossperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustment for share instruments (in shares)", "label": "Dilutive effect of convertible instruments on weighted average number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments." } } }, "auth_ref": [ "r412" ] }, "inpha_DisclosureOfActuarialAssumptionsForDefinedBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfActuarialAssumptionsForDefinedBenefitPlansTextBlock", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of actuarial assumptions for defined benefit plans", "label": "Disclosure Of Actuarial Assumptions For Defined Benefit Plans [Text Block]", "documentation": "The disclosure of actuarial assumptions for defined benefit plans." } } }, "auth_ref": [] }, "inpha_DisclosureOfAuditAndNonAuditFeesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfAuditAndNonAuditFeesTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of audit and non-audit fees", "label": "Disclosure Of Audit And Non-audit Fees [Table Text Block]", "documentation": "The disclosure for audit and non-audit fees." } } }, "auth_ref": [] }, "inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of cash, cash equivalents and financial assets", "label": "Disclosure Of Cash, Cash Equivalents And Financial Assets [Text Block]", "documentation": "The disclosure of cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "inpha_DisclosureOfChangeInNumberOfOtherEquityInstrumentsOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfChangeInNumberOfOtherEquityInstrumentsOutstandingTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of change in number of other equity instruments outstanding", "label": "Disclosure Of Change In Number Of Other Equity Instruments Outstanding [Table Text Block]", "documentation": "Disclosure of change in number of other equity instruments outstanding." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsTables", "http://www.innate-pharma.com/role/ThecompanyTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in share capital", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r145", "r201", "r234" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in the share capital", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [Table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r145", "r201", "r234" ] }, "inpha_DisclosureOfClosingBalanceOfShareBasedPaymentArrangementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfClosingBalanceOfShareBasedPaymentArrangementsTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of closing balance of share-based payment arrangements", "label": "Disclosure Of Closing Balance Of Share-based Payment Arrangements [Table Text Block]", "documentation": "The entire disclosure for closing balance of of share-based payment arrangements." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigations" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments, contingencies and litigations", "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r424" ] }, "inpha_DisclosureOfCompanySignificantContractsAndKeyEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfCompanySignificantContractsAndKeyEventsTextBlock", "presentation": [ "http://www.innate-pharma.com/role/Thecompany" ], "lang": { "en-us": { "role": { "terseLabel": "The company", "label": "Disclosure Of Company, Significant Contracts And Key Events [Text Block]", "documentation": "The disclosure of the company, significant agreements description and key events." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [table]", "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [table]", "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r35", "r172" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans", "label": "Disclosure of defined benefit plans [text block]" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r11", "r160" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [line items]", "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [table]", "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r11", "r160" ] }, "inpha_DisclosureOfDepreciationPeriodsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfDepreciationPeriodsTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of depreciation periods", "label": "Disclosure Of Depreciation Periods [Table Text Block]", "documentation": "The disclosure of depreciation period." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments", "label": "Disclosure of detailed information about financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r99", "r102", "r108", "r185" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r43", "r180" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r9", "r158" ] }, "inpha_DisclosureOfDetailedInformationAboutTradePayablesAndOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradePayablesAndOthersLineItems", "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Trade Payables And Others [Line Items]", "label": "Disclosure Of Detailed Information About Trade Payables And Others [Line Items]", "documentation": "Disclosure Of Detailed Information About Trade Payables And Others [Line Items]" } } }, "auth_ref": [] }, "inpha_DisclosureOfDetailedInformationAboutTradePayablesAndOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradePayablesAndOthersTable", "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Trade Payables And Others [Table]", "label": "Disclosure Of Detailed Information About Trade Payables And Others [Table]", "documentation": "Disclosure Of Detailed Information About Trade Payables And Others [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [abstract]", "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of revenue from collaboration and licensing agreements", "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]" } } }, "auth_ref": [ "r79", "r132" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails", "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails", "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]", "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r79", "r132" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Incomelosspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of effect of changes in foreign exchange rates", "label": "Disclosure of effect of changes in foreign exchange rates [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r18" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Employeebenefits" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Disclosure of employee benefits [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r16" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Eventsafterthereportingdate" ], "lang": { "en-us": { "role": { "terseLabel": "Events after the reporting date", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r0" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of expenses by nature", "label": "Disclosure of expenses by nature [text block]" } } }, "auth_ref": [ "r424" ] }, "ifrs-full_DisclosureOfExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Operatingexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Disclosure of expenses [text block]" } }, "en": { "role": { "documentation": "The disclosure of expenses." } } }, "auth_ref": [ "r424" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Netfinancialincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Net financial income (loss)", "label": "Disclosure of finance income (cost) [text block]" } } }, "auth_ref": [ "r424" ] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Cashcashequivalentsandfinancialassets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and financial assets", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r108", "r185" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [Line Items]", "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [Table]", "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r108", "r185" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [abstract]", "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments recognized in the statement of financial position and related effect on the income statement", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r115" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails", "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [line items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails", "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r99", "r102", "r108", "r185" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [abstract]" } } }, "auth_ref": [] }, "inpha_DisclosureOfFinancialLiabilitiesClassifiedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfFinancialLiabilitiesClassifiedTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of schedule for the contractual flows of financial liabilities", "label": "Disclosure Of Financial Liabilities, Classified [Table Text Block]", "documentation": "The disclosure of financial liabilities, classified." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Financialliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r108", "r185" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [Line Items]", "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities per maturity", "label": "Disclosure Of Financial Liabilities Per Maturity [Table Text Block]", "documentation": "The disclosure of financial liabilities per maturity." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [Table]", "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r108", "r185" ] }, "inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of government financing for research expenditures", "label": "Disclosure Of Government Financing For Research Expenditures [Table Text Block]", "documentation": "The disclosure of government financing for research expenditures." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.innate-pharma.com/role/IncomeTax" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of information about defined benefit plans [abstract]", "label": "Disclosure of information about defined benefit plans [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of initial application of standards or interpretations [Line Items]", "label": "Disclosure of initial application of standards or interpretations [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of initial application of standards or interpretations[Table]", "label": "Disclosure of initial application of standards or interpretations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the initial application of standards or interpretations." } } }, "auth_ref": [ "r55", "r150" ] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r45" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r43", "r180" ] }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIssuedCapitalExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Sharecapitalandsharebasedpayments" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital and share based payments", "label": "Disclosure of issued capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r424" ] }, "inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of key management personnel compensation", "label": "Disclosure Of Key Management Personnel Compensation [Table Text Block]", "documentation": "The disclosure for key management personnel compensation." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Accountingpoliciesandstatementofcompliance" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting policies and statement of compliance", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r149", "r202", "r214" ] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [abstract]", "label": "Disclosure of nature and extent of risks arising from financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Managementoffinancialrisksandfairvalue" ], "lang": { "en-us": { "role": { "terseLabel": "Management of financial risks and fair value", "label": "Disclosure of nature and extent of risks arising from financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r99" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net defined benefit liability (asset)", "label": "Disclosure of net defined benefit liability (asset) [text block]" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r12", "r161" ] }, "inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfNetFinancialIncomeLossTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net financial loss", "label": "Disclosure Of Net Financial Income (Loss) [Table Text Block]", "documentation": "The disclosure of net financial income (loss)." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [abstract]", "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average exercise prices of other equity instruments", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r421" ] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement Line Items [Line Items]", "label": "Disclosure of operating segments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating segments [Table]", "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r120" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Propertyandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r10" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails", "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [Line Items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails", "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r9", "r158" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments", "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in the loss allowance and explanation of changes in the gross carrying amount for financial instruments. Loss allowance is the allowance for expected credit losses on financial assets measured in accordance with paragraph 4.1.2 of IFRS 9, lease receivables and contract assets, the accumulated impairment amount for financial assets measured in accordance with paragraph 4.1.2A of IFRS 9 and the provision for expected credit losses on loan commitments and financial guarantee contracts. [Refer: Gross carrying amount [member]]" } } }, "auth_ref": [ "r100", "r101", "r191", "r192" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Relatedpartytransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r26" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Revenueandgovernmentfinancingforresearchexpenditures" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and government financing for research expenditures", "label": "Disclosure of revenue [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r424" ] }, "inpha_DisclosureOfTaxRateReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfTaxRateReconciliationTextBlock", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of tax rate reconciliation", "label": "Disclosure Of Tax Rate Reconciliation [Text Block]", "documentation": "The disclosure of tax rate reconciliation." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r6", "r156" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r6", "r156" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of other equity instruments", "label": "Disclosure of terms and conditions of share-based payment arrangement [text block]" } }, "en": { "role": { "documentation": "The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r93", "r184" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Line Items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r93", "r184" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Tradepayablesandothers" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r424" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Tradereceivablesandothers" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r424" ] }, "inpha_DisclosureOfTradePayablesAndOthersTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfTradePayablesAndOthersTextBlock", "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade payables and others", "label": "Disclosure Of Trade Payables And Others [Text Block]", "documentation": "The disclosure of trade payables and others." } } }, "auth_ref": [] }, "inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfTradeReceivablesAndOtherTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade receivables and other", "label": "Disclosure Of Trade Receivables And Other [Table Text Block]", "documentation": "The disclosure of trade receivables and other." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r23", "r167" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [Line Items]", "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [Table]", "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r24", "r168" ] }, "inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisclosureOfVarianceOfDeferredRevenueTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of variance of deferred revenue", "label": "Disclosure Of Variance Of Deferred Revenue [Table Text Block]", "documentation": "The disclosure of variance of deferred revenue." } } }, "auth_ref": [] }, "inpha_DisposalOfCurrentFinancialInstrumentsAndPaidInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisposalOfCurrentFinancialInstrumentsAndPaidInterests", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of current financial instruments and paid interests", "label": "Disposal Of Current Financial Instruments And Paid Interests", "documentation": "The cash inflow from the disposal of current financial instruments." } } }, "auth_ref": [] }, "inpha_DisposalOfNonCurrentFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DisposalOfNonCurrentFinancialInstruments", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of non-current financial instruments", "label": "Disposal Of Non-current Financial Instruments", "documentation": "The cash inflow from the disposal of non-current financial instruments." } } }, "auth_ref": [] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r38", "r175" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals", "label": "Disposals, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r405" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r294" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r293", "r294", "r317" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r293", "r294", "r317", "r360" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Restatement Recovery Analysis [Flag]", "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r293", "r294", "r317", "r360" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r289" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r294" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r338" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "inpha_DownPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "DownPaymentMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property transaction (down-payment)", "label": "Down-payment [Member]", "documentation": "This member stands for down-payment." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of income (loss) per share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of the exchange rate changes", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r48", "r49" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Personnel expenses", "label": "Employee benefits expense" } } }, "auth_ref": [ "r141", "r208", "r243", "r283" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "inpha_EmployeesBornAfter1January1968Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "EmployeesBornAfter1January1968Member", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees born after 1 January 1968", "label": "Employees Born After 1 January 1968 [Member]", "documentation": "Employees Born After 1 January 1968" } } }, "auth_ref": [] }, "inpha_EmployeesBornBefore1January1968Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "EmployeesBornBefore1January1968Member", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees born before 1 January 1968", "label": "Employees Born Before 1 January 1968 [Member]", "documentation": "Employees Born Before 1 January 1968" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesLineItems", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses [Line Items]", "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesTable", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses [Table]", "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r291" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r291" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r291" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r291" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r400" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r291" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r291" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r401" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r343" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r396" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r396" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r396" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "terseLabel": "Total equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r56", "r58", "r72", "r73", "r74", "r169", "r182", "r195", "r196", "r205", "r221", "r230" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r221" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r353" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r310", "r321", "r331", "r364" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r307", "r318", "r328", "r361" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExchangeDomain", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r359" ] }, "inpha_ExecutivesBornAfter1968Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExecutivesBornAfter1968Member", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executives, born after 1968", "label": "Executives, Born After 1968 [Member]", "documentation": "Executives, Born After 1968" } } }, "auth_ref": [] }, "inpha_ExecutivesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExecutivesMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executives", "label": "Executives [Member]", "documentation": "This member stands for executives." } } }, "auth_ref": [] }, "inpha_ExerciseAndSubscriptionOfEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExerciseAndSubscriptionOfEquityInstruments", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise and subscription of equity instruments", "verboseLabel": "Exercise and subscription of equity instruments", "label": "Exercise And Subscription Of Equity Instruments", "documentation": "The increase (decrease) in equity resulting from exercise and subscription of equity instruments." } } }, "auth_ref": [] }, "inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExerciseAndSubscriptionOfEquityInstrumentsInShares", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise and subscription of equity instruments (in shares)", "label": "Exercise And Subscription Of Equity Instruments, In Shares", "documentation": "The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments." } } }, "auth_ref": [] }, "inpha_ExerciseOfShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExerciseOfShareWarrantsMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share warrants", "label": "Exercise Of Share Warrants [Member]", "documentation": "Exercise Of Share Warrants" } } }, "auth_ref": [] }, "inpha_ExercisePeriodTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExercisePeriodTerms", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise period, terms", "label": "Exercise Period, Terms", "documentation": "Exercise Period, Terms" } } }, "auth_ref": [] }, "inpha_ExercisePriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExercisePriceOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in EUR per share)", "label": "Exercise Price Other Equity Instruments Granted", "documentation": "The exercise price of other equity instruments granted." } } }, "auth_ref": [] }, "inpha_ExpectedDecreaseInNumberOfEmployeesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExpectedDecreaseInNumberOfEmployeesPercentage", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected decrease in number of employees, percentage", "label": "Expected Decrease In Number Of Employees, Percentage", "documentation": "Expected Decrease In Number Of Employees, Percentage" } } }, "auth_ref": [] }, "inpha_ExpectedDividendOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExpectedDividendOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected dividends", "terseLabel": "Expected dividends", "label": "Expected Dividend Other Equity Instruments Granted", "documentation": "The amount of an expected dividend used to calculate the fair value of other equity instruments granted." } } }, "auth_ref": [] }, "inpha_ExpectedTurnoverOtherInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExpectedTurnoverOtherInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected turnover (yearly basis)", "label": "Expected Turnover Other Instruments Granted", "documentation": "The expected turnover of other instruments granted." } } }, "auth_ref": [] }, "inpha_ExpectedVolatilityOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Volatility", "terseLabel": "Expected volatility", "label": "Expected Volatility Other Equity Instruments Granted", "documentation": "The expected volatility of the share price used to calculate the fair value of the other equity instruments granted." } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense from share-based payment transactions with employees", "verboseLabel": "Share-based compensation", "negatedTerseLabel": "Share-based compensation", "label": "Expense from share-based payment transactions with employees" } } }, "auth_ref": [ "r429" ] }, "ifrs-full_ExpenseOfRestructuringActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseOfRestructuringActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring costs", "label": "Expense of restructuring activities" } } }, "auth_ref": [ "r242" ] }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of breakdown of expenses per financial year", "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]" } }, "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in deferred revenue and collaboration liabilities", "label": "Explanation of significant changes in contract assets and contract liabilities [text block]" } }, "en": { "role": { "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]" } } }, "auth_ref": [ "r81" ] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax losses carryforwards - France", "label": "FRANCE" } } }, "auth_ref": [] }, "inpha_FairValuePerShareAtGrantDateOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FairValuePerShareAtGrantDateOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value per AGA (in EUR per share)", "terseLabel": "Fair value per BSA (in EUR per share)", "label": "Fair Value Per Share At Grant Date Other Equity Instruments Granted", "documentation": "The fair value per share at grant date of other equity instruments granted." } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial expenses", "negatedTotalLabel": "Financial expenses", "label": "Finance costs" } } }, "auth_ref": [ "r239" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income", "totalLabel": "Financial income", "label": "Finance income" } } }, "auth_ref": [ "r438" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net financial income (loss)", "label": "Finance income (cost)" } } }, "auth_ref": [ "r438" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial assets", "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r98", "r100", "r101", "r103", "r191", "r192", "r193", "r269" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial assets, fair value", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value through profit or loss", "label": "Financial assets at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r109", "r186" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total financial liabilities", "verboseLabel": "Financial liabilities", "periodStartLabel": "Financial liabilities at beginning of period", "periodEndLabel": "Financial liabilities at end of period", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt at amortized cost", "label": "Financial liabilities at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r111", "r188" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value through profit or loss", "label": "Financial liabilities at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r110", "r187" ] }, "inpha_FinancialLiabilitiesCurrentPortionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FinancialLiabilitiesCurrentPortionMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities\u2014current portion", "label": "Financial Liabilities, Current Portion [Member]", "documentation": "This member stands for financial liabilities\u2014current portion." } } }, "auth_ref": [] }, "inpha_FinancialLiabilitiesDownPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FinancialLiabilitiesDownPayment", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Financial liabilities down payment at beginning of period", "negatedPeriodEndLabel": "Financial liabilities down payment at end of period", "label": "Financial Liabilities Down Payment", "documentation": "The amount of down payment in connection with the financial liabilities." } } }, "auth_ref": [] }, "inpha_FinancialLiabilitiesNonCurrentPortionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FinancialLiabilitiesNonCurrentPortionMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities\u2014non-current portion", "label": "Financial Liabilities, Non-current Portion [Member]", "documentation": "This member stands for financial liabilities\u2014non-current portion." } } }, "auth_ref": [] }, "inpha_FinancialLiabilitiesTradePayablesAndOthers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FinancialLiabilitiesTradePayablesAndOthers", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial liabilities", "label": "Financial Liabilities Trade Payables And Others", "documentation": "The amount of financial liabilities, trade payables and others." } } }, "auth_ref": [] }, "inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FinancialLiabilitiesTradePayablesAndOthersAtFairValue", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial liabilities, fair value", "label": "Financial Liabilities Trade Payables And Others At Fair Value", "documentation": "The fair value of financial liabilities, trade payables and other." } } }, "auth_ref": [] }, "inpha_FinancialTransactionsRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FinancialTransactionsRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial transactions, related party transactions", "label": "Financial Transactions, Related Party Transactions", "documentation": "Financial Transactions, Related Party Transactions" } } }, "auth_ref": [] }, "ifrs-full_FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixedInterestRateMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Fixed interest rate [member]" } }, "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r422" ] }, "inpha_ForeignExchangeGainLossContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ForeignExchangeGainLossContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fx impact", "label": "Foreign Exchange Gain (Loss), Contract Liabilities", "documentation": "Foreign Exchange Gain (Loss), Contract Liabilities" } } }, "auth_ref": [] }, "inpha_ForeignExchangeGainLossCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ForeignExchangeGainLossCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fx impact", "label": "Foreign Exchange Gain (Loss), Current Contract Liabilities", "documentation": "Foreign Exchange Gain (Loss), Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_ForeignExchangeGainLossNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ForeignExchangeGainLossNonCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fx impact", "label": "Foreign Exchange Gain (Loss), Non Current Contract Liabilities", "documentation": "Foreign Exchange Gain (Loss), Non Current Contract Liabilities" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r314", "r325", "r335", "r368" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r314", "r325", "r335", "r368" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r314", "r325", "r335", "r368" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r314", "r325", "r335", "r368" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r314", "r325", "r335", "r368" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r348" ] }, "inpha_FreePerformancesSharesPlansPerformancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "FreePerformancesSharesPlansPerformancePercentage", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Free performances shares plans, performance (in percents)", "label": "Free Performances Shares Plans, Performance Percentage", "documentation": "Free Performances Shares Plans, Performance Percentage" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial (loss) gain", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r13", "r162" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "label": "General and administrative expense" } } }, "auth_ref": [ "r429" ] }, "inpha_GeneralAndAdministrativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "GeneralAndAdministrativeMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "G&A", "label": "General And Administrative [Member]", "documentation": "General And Administrative" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r127", "r246", "r264", "r268", "r279" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [domain]", "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r127", "r246", "r264", "r268", "r279" ] }, "inpha_GovernmentFinancingForResearchExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "GovernmentFinancingForResearchExpenditures", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofGovernmentFinancingforResearchExpendituresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofGovernmentFinancingforResearchExpendituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government financing for research expenditures", "totalLabel": "Government financing for research expenditures", "label": "Government Financing For Research Expenditures", "documentation": "The amount of income recognised in relation to government financing for research expenditures." } } }, "auth_ref": [] }, "inpha_GrantDateShareFairValueOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "GrantDateShareFairValueOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Grant date share fair value (in EUR per share)", "terseLabel": "Grant date share fair value (in EUR per share)", "label": "Grant Date Share Fair Value Other Equity Instruments Granted", "documentation": "The grant date share fair value of other equity instruments granted." } } }, "auth_ref": [] }, "ifrs-full_GuaranteesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GuaranteesMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantees", "label": "Guarantees [member]" } }, "en": { "role": { "documentation": "This member stands for formal promises, often in writing, in which one party assumes responsibility for another's debts or responsibilities, or in which the party provides assurance that certain conditions will be fulfilled." } } }, "auth_ref": [ "r272" ] }, "inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPH5201 (Anti-CD39) rights acquired from Orega Biotech", "label": "IPH5201 (Anti-CD39) Rights Acquired From Orega Biotech [Member]", "documentation": "This member stands for IPH5201 (Anti-CD39) rights acquired from Orega Biotech." } } }, "auth_ref": [] }, "inpha_IPH5201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IPH5201Member", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi options", "label": "IPH5201 [Member]", "documentation": "This member stands for IPH5201." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r293", "r294", "r317" ] }, "inpha_ImpairmentLossMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ImpairmentLossMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Impairment Loss [Member]", "documentation": "Impairment Loss" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment of intangible assets", "terseLabel": "Impairment of intangible assets", "negatedNetLabel": "Impairment", "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill" } } }, "auth_ref": [ "r39", "r176" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossTradeReceivables", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss recognised in profit or loss, trade receivables", "label": "Impairment loss recognised in profit or loss, trade receivables" } } }, "auth_ref": [ "r429" ] }, "inpha_IncomeFromResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncomeFromResearchTaxCredit", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofGovernmentFinancingforResearchExpendituresDetails": { "parentTag": "inpha_GovernmentFinancingForResearchExpenditures", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofGovernmentFinancingforResearchExpendituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit", "label": "Income From Research Tax Credit", "documentation": "The amount of income related to research tax credit." } } }, "auth_ref": [] }, "inpha_IncomeFromResearchTaxCredit2019": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncomeFromResearchTaxCredit2019", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from research tax credit 2019", "label": "Income From Research Tax Credit 2019", "documentation": "Income From Research Tax Credit 2019" } } }, "auth_ref": [] }, "inpha_IncomeFromResearchTaxCredit2020": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncomeFromResearchTaxCredit2020", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from research tax credit 2020", "label": "Income From Research Tax Credit 2020", "documentation": "Income From Research Tax Credit 2020" } } }, "auth_ref": [] }, "inpha_IncomeFromResearchTaxCredit2023": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncomeFromResearchTaxCredit2023", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from research tax credit 2023", "label": "Income From Research Tax Credit 2023", "documentation": "Income From Research Tax Credit 2023" } } }, "auth_ref": [] }, "inpha_IncomeLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncomeLossPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) Per Share [Abstract]", "label": "Income (Loss) Per Share [Abstract]" } } }, "auth_ref": [] }, "inpha_IncomeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncomeTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax [Abstract]", "label": "Income Tax [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": -1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "negatedTotalLabel": "Income tax benefit / (expense)", "label": "Tax expense (income)" } } }, "auth_ref": [ "r1", "r2", "r3", "r28", "r71", "r119", "r151", "r152", "r153", "r240" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income taxes refund, classified as operating activities", "label": "Income taxes paid (refund), classified as operating activities" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r51", "r252" ] }, "inpha_IncreaseCapitalNetInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseCapitalNetInShares", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase capital, net (in shares)", "label": "Increase Capital, Net (In Shares)", "documentation": "The increase (decrease) in the number of shares issued resulting from the new shares issued during period." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) due to changes in accounting policy required by IFRSs", "label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]" } } }, "auth_ref": [ "r427" ] }, "inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, variation of accrued interest", "label": "Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss", "documentation": "Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss" } } }, "auth_ref": [] }, "inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, variation of accrued interest", "label": "Increase (Decrease) In Accrued Interest For Non-current Financial Assets Not At Fair Value Through Profit Or Loss", "documentation": "The amount of income arising from interest for non-current financial assets that are not at fair value through profit or loss." } } }, "auth_ref": [] }, "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, variance of accrued interest", "label": "Increase (Decrease) In Accrued Interest For Short-term And Non-current Financial Assets Not At Fair Value Through Profit Or Loss", "documentation": "The amount of income arising from interest for short-term and non-current financial assets that are not at fair value through profit or loss." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase / (decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r53", "r148" ] }, "inpha_IncreaseDecreaseInEmployeeBenefitObligationPer25BasisPointChangesInDiscountRate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseDecreaseInEmployeeBenefitObligationPer25BasisPointChangesInDiscountRate", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in employee benefit obligation per 25 basis point changes in discount rate", "label": "Increase (Decrease) In Employee Benefit Obligation Per 25 Basis Point Changes In Discount Rate", "documentation": "The amount increase (decrease) in employee benefit obligation per 25 basis point changes in discount rate." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromMiscellaneousOtherChanges", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring impact", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from miscellaneous other changes" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from miscellaneous other changes. [Refer: Net defined benefit liability (asset); Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss; Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r407" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase capital, net (in shares)", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r429" ] }, "inpha_IncreaseDecreaseInNumberOfSharesIssuedFromConversionOfEquityInstruments": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseDecreaseInNumberOfSharesIssuedFromConversionOfEquityInstruments", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise and subscription of equity instruments through conversion (in shares)", "label": "Increase (Decrease) In Number Of Shares Issued From Conversion Of Equity Instruments", "documentation": "The number of increase (decrease) in shares issued from the conversion of equity instruments." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in working capital", "negatedTotalLabel": "Change in working capital, variance", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r420" ] }, "inpha_IncreaseDecreaseInWorkingCapitalBeforeAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseDecreaseInWorkingCapitalBeforeAdjustments", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Change in working capital, variance", "label": "Increase (Decrease) In Working Capital, Before Adjustments", "documentation": "Increase (Decrease) In Working Capital, Before Adjustments" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of prior period loss", "label": "Increase (decrease) through appropriation of retained earnings, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r426" ] }, "inpha_IncreaseDecreaseThroughConversionOfEquityInstrumentsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseDecreaseThroughConversionOfEquityInstrumentsEquity", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise and subscription of equity instruments through conversion", "label": "Increase (Decrease) Through Conversion Of Equity Instruments Equity", "documentation": "The amount of increase (decrease) through conversion of equity instruments." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange variation", "label": "Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r405" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers", "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from transfers from construction in progress. [Refer: Property, plant and equipment including right-of-use assets; Construction in progress]" } } }, "auth_ref": [ "r405" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers", "label": "Increase (decrease) through transfers, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r414" ] }, "inpha_IncreaseInNetDefinedBenefitLiabilityAssetResultingFromCurrentServiceAndActualizationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseInNetDefinedBenefitLiabilityAssetResultingFromCurrentServiceAndActualizationCosts", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service and actualization costs", "label": "Increase In Net Defined Benefit Liability (Asset) Resulting From Current Service And Actualization Costs", "documentation": "Increase In Net Defined Benefit Liability (Asset) Resulting From Current Service And Actualization Costs" } } }, "auth_ref": [] }, "inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase Through Performance Obligation Being Satisfied, Contract Liabilities", "documentation": "The increase in contract liabilities resulting from additions." } } }, "auth_ref": [] }, "inpha_IncreaseThroughPerformanceObligationBeingSatisfiedCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseThroughPerformanceObligationBeingSatisfiedCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities", "documentation": "Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_IncreaseThroughPerformanceObligationBeingSatisfiedNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseThroughPerformanceObligationBeingSatisfiedNonCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities", "documentation": "Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_IncreaseThroughUpfrontPaymentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IncreaseThroughUpfrontPaymentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds", "label": "Increase Through Upfront Payment Contract Liabilities", "documentation": "The increase in contract liabilities resulting from upfront payment." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r314", "r325", "r335", "r359", "r368", "r372", "r380" ] }, "inpha_InnatePharmaTreasuryStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "InnatePharmaTreasuryStockMember", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Innate Pharma, Treasury Stock [Member]", "documentation": "Innate Pharma, Treasury Stock" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r378" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r295", "r384" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r295", "r384" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r295", "r384" ] }, "inpha_InstallationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "InstallationsMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installations", "label": "Installations [Member]", "documentation": "This member stands for installations." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Intangible assets other than goodwill at beginning of period", "periodEndLabel": "Intangible assets other than goodwill at end of period", "verboseLabel": "Intangible assets other than goodwill", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r42", "r179", "r215" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillAbstract", "lang": { "en-us": { "role": { "terseLabel": "Intangible assets other than goodwill [abstract]", "label": "Intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsUnderDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsUnderDevelopmentMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In progress", "label": "Intangible assets under development [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r251" ] }, "inpha_IntellectualPropertyExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IntellectualPropertyExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intellectual property expenses", "label": "Intellectual Property Expenses", "documentation": "The amount of intellectual property expenses." } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest on financial liabilities", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r70", "r117", "r124" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid, classified as operating activities", "label": "Interest paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received on financial assets", "label": "Interest received, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsOperatingActivities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as operating activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } } }, "auth_ref": [ "r50" ] }, "inpha_InterestsAndGainsOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "InterestsAndGainsOnFinancialAssets", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interests and gains on financial assets", "label": "Interests And Gains On Financial Assets", "documentation": "The amount of interests and gains on financial assets." } } }, "auth_ref": [] }, "inpha_InternalConditionsPerformanceRevenueFromCollaborationAndLicensingAgreementsMinimumAccrualBetweenAttributionAndDefinitiveAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "InternalConditionsPerformanceRevenueFromCollaborationAndLicensingAgreementsMinimumAccrualBetweenAttributionAndDefinitiveAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaboration and licensing agreements, minimum accrual between attribution and definitive acquisition date", "label": "Internal Conditions Performance, Revenue From Collaboration And Licensing Agreements, Minimum Accrual Between Attribution And Definitive Acquisition Date", "documentation": "Internal Conditions Performance, Revenue From Collaboration And Licensing Agreements, Minimum Accrual Between Attribution And Definitive Acquisition Date" } } }, "auth_ref": [] }, "inpha_InvoicingResearchAndDevelopmentCostsIPH5201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "InvoicingResearchAndDevelopmentCostsIPH5201Member", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invoicing of research and development costs (IPH5201)", "label": "Invoicing Research And Development Costs IPH5201 [Member]", "documentation": "Invoicing Research And Development Costs IPH5201" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase capital, net", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r212" ] }, "inpha_IssueOfEquitySharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IssueOfEquitySharePrice", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in EUR per share)", "label": "Issue of Equity, Share Price", "documentation": "Issue of Equity, Share Price" } } }, "auth_ref": [] }, "inpha_IssueSharesForLicenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "IssueSharesForLicenses", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue shares for licenses", "label": "Issue Shares For Licenses", "documentation": "The value of shares issued related to licenses." } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r282", "r288" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Executive Committee & Board members compensation", "label": "Key management personnel compensation" } } }, "auth_ref": [ "r21", "r165" ] }, "inpha_KeyManagementPersonnelCompensationAdvisoryFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "KeyManagementPersonnelCompensationAdvisoryFees", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory fees", "label": "Key Management Personnel Compensation, Advisory Fees", "documentation": "Key Management Personnel Compensation, Advisory Fees" } } }, "auth_ref": [] }, "inpha_KeyManagementPersonnelCompensationExtraPensionBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "KeyManagementPersonnelCompensationExtraPensionBenefits", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extra pension benefits", "label": "Key Management Personnel Compensation Extra Pension Benefits", "documentation": "Key Management Personnel Compensation Extra Pension Benefits" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r20" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Personnel expenses and other short-term employee benefits", "label": "Key management personnel compensation, short-term employee benefits" } } }, "auth_ref": [ "r19" ] }, "inpha_LaboratoryEquipmentAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LaboratoryEquipmentAndOtherMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment and other", "label": "Laboratory Equipment And Other [Member]", "documentation": "This member stands for laboratory equipment and other." } } }, "auth_ref": [] }, "ifrs-full_LandAndBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LandAndBuildingsMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land and buildings", "label": "Land and buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": ">2030", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r85", "r86", "r90", "r136", "r139", "r270", "r273", "r275" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030", "label": "Later than four years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r85", "r86", "r90", "r270", "r275", "r429" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r85", "r86", "r90", "r270", "r275", "r429" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Later than three years and not later than four years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r85", "r86", "r90", "r270", "r275", "r429" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Later than two years and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r85", "r86", "r90", "r270", "r275", "r429" ] }, "inpha_LeaseContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseContractMember", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities / Lease contract (IFRS 16 application)", "label": "Lease Contract [Member]", "documentation": "Lease Contract" } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsBuildingLeVirageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseFinancingObligationsBuildingLeVirageMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Building \"Le Virage\"", "verboseLabel": "Lease finance obligations \u2013 Rent Le Virage", "label": "Lease Financing Obligations, Building, \"Le Virage\" [Member]", "documentation": "Related to the finance lease obligations for the \"Le Virage\" building." } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseFinancingObligationsEquipmentMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Laboratory equipment", "verboseLabel": "Lease finance obligations \u2013 Laboratory equipment", "label": "Lease Financing Obligations, Equipment [Member]", "documentation": "This member stands for lease finance obligations, equipment." } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsITSecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseFinancingObligationsITSecurityMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities - IT security", "label": "Lease Financing Obligations, IT Security [Member]", "documentation": "Lease Financing Obligations, IT Security" } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsInnateIncPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseFinancingObligationsInnateIncPremisesMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Premises Innate Inc.", "label": "Lease Financing Obligations, Innate Inc. Premises [Member]", "documentation": "Related to the lease financing obligations for the Innate Inc. premises." } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsPrintersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseFinancingObligationsPrintersMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities - Printers", "label": "Lease Financing Obligations, Printers [Member]", "documentation": "Lease Financing Obligations, Printers" } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsRealEstatePropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseFinancingObligationsRealEstatePropertyMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Real estate property", "label": "Lease Financing Obligations, Real Estate Property [Member]", "documentation": "This member stands for lease finance obligations, real estate property." } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeaseFinancingObligationsVehiclesMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Vehicles", "label": "Lease Financing Obligations, Vehicles [Member]", "documentation": "Related to the lease financing obligation for vehicles." } } }, "auth_ref": [] }, "inpha_LeasingAndMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LeasingAndMaintenance", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Leasing and maintenance", "label": "Leasing And Maintenance", "documentation": "The amount of leasing and maintenance." } } }, "auth_ref": [] }, "inpha_LengthOfServiceAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LengthOfServiceAwardsMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Length of service awards", "label": "Length Of Service Awards [Member]", "documentation": "Length Of Service Awards" } } }, "auth_ref": [] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Net defined benefit liability (asset) at beginning of period", "periodEndLabel": "Net defined benefit liability (asset) at end of period", "label": "Net defined benefit liability (asset)" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r12", "r161" ] }, "ifrs-full_LicencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LicencesMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased licenses", "label": "Licences [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r415" ] }, "inpha_LicensingAgreementMaximumMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LicensingAgreementMaximumMilestonePayment", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing agreement, maximum milestone payment", "label": "Licensing Agreement, Maximum Milestone Payment", "documentation": "Licensing Agreement, Maximum Milestone Payment" } } }, "auth_ref": [] }, "inpha_LoanAgreementCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LoanAgreementCollateral", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement, collateral", "label": "Loan Agreement Collateral", "documentation": "The value of collateral in connection with the loan agreement." } } }, "auth_ref": [] }, "inpha_LoanAgreementMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LoanAgreementMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement, maximum borrowing capacity", "label": "Loan Agreement Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the loan agreement." } } }, "auth_ref": [] }, "inpha_LoanAgreementWithSocitGnraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LoanAgreementWithSocitGnraleMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement with Soci\u00e9t\u00e9 G\u00e9n\u00e9rale", "label": "Loan Agreement With Soci\u00e9t\u00e9 G\u00e9n\u00e9rale [Member]", "documentation": "This member stands for loan agreement with Soci\u00e9t\u00e9 G\u00e9n\u00e9rale." } } }, "auth_ref": [] }, "inpha_LoanBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LoanBuildingMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan \u2013 Building", "verboseLabel": "Loan, building", "label": "Loan, Building [Member]", "documentation": "This member stands for loan, building." } } }, "auth_ref": [] }, "inpha_LoanEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "LoanEquipmentMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans \u2013 Equipment", "label": "Loan, Equipment [Member]", "documentation": "This member stands for loan, equipment." } } }, "auth_ref": [] }, "ifrs-full_LoansAndReceivablesCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansAndReceivablesCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables", "label": "Loans and receivables, category [member]" } }, "en": { "role": { "documentation": "This member stands for the loans and receivables category of financial assets. [Refer: Loans and receivables]" } } }, "auth_ref": [ "r206" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r104", "r194" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r82", "r85", "r86", "r87", "r88", "r89", "r90", "r97", "r105", "r131", "r134", "r137", "r140", "r190", "r224", "r248", "r270" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [domain]", "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r82", "r85", "r86", "r87", "r88", "r89", "r90", "r97", "r131", "r134", "r137", "r140", "r190", "r224", "r248", "r270", "r274" ] }, "inpha_MaximumAmountReceivableFromCounterPartyUponAchievementOfCertainDevelopmentMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MaximumAmountReceivableFromCounterPartyUponAchievementOfCertainDevelopmentMilestones", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount receivable from counter party upon achievement of certain development milestones", "label": "Maximum Amount Receivable From Counter Party Upon Achievement Of Certain Development Milestones", "documentation": "The maximum amount receivable from counter party upon achievement of certain development milestones." } } }, "auth_ref": [] }, "inpha_MaximumAmountReceivableFromCounterPartyUponAchievementOfCertainMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MaximumAmountReceivableFromCounterPartyUponAchievementOfCertainMilestones", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount receivable from counter party upon achievement of certain milestones", "label": "Maximum Amount Receivable From Counter Party Upon Achievement Of Certain Milestones", "documentation": "The maximum amount that receivable from counter party upon achievement of certain development and regulatory milestones and commercialization milestones." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "inpha_MaximumPaymentsToCounterPartyUponAchievementOfCertainMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MaximumPaymentsToCounterPartyUponAchievementOfCertainMilestones", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum payments to counter party upon achievement of certain milestones", "label": "Maximum Payments To Counter Party Upon Achievement Of Certain Milestones", "documentation": "The maximum payments to counter party upon the achievement of certain commercial and regulatory milestones." } } }, "auth_ref": [] }, "inpha_MaximumPotentialRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MaximumPotentialRegulatoryMilestones", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum potential regulatory milestones", "label": "Maximum Potential Regulatory Milestones", "documentation": "Maximum Potential Regulatory Milestones" } } }, "auth_ref": [] }, "inpha_MaximumPotentialRegulatoryMilestonesAndSingleDigitTieredRoyaltiesOnSaleOfProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MaximumPotentialRegulatoryMilestonesAndSingleDigitTieredRoyaltiesOnSaleOfProducts", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum potential regulatory milestones and single-digit tiered royalties on sale of products", "label": "Maximum Potential Regulatory Milestones And Single-digit Tiered Royalties On Sale Of Products", "documentation": "The maximum amount of potential regulatory milestones and single-digit tiered royalties on sale of products." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r351" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r351" ] }, "inpha_MedimmuneLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MedimmuneLimitedMember", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medimmune Limited", "label": "Medimmune Limited [Member]", "documentation": "Medimmune Limited" } } }, "auth_ref": [] }, "inpha_MembersOfTheExecutiveBoardSupervisoryBoardAndLeadershipTeamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MembersOfTheExecutiveBoardSupervisoryBoardAndLeadershipTeamMember", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Members of the Executive Board, Supervisory Board and Leadership Team", "label": "Members of the Executive Board, Supervisory Board and Leadership Team [Member]", "documentation": "Members of the Executive Board, Supervisory Board and Leadership Team" } } }, "auth_ref": [] }, "inpha_MilestonePaymentsMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MilestonePaymentsMaximumAmount", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments, maximum amount", "label": "Milestone Payments, Maximum Amount", "documentation": "Milestone Payments, Maximum Amount" } } }, "auth_ref": [] }, "inpha_MilestonePaymentsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MilestonePaymentsPercentage", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments, percentage", "label": "Milestone Payments, Percentage", "documentation": "Milestone Payments, Percentage" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r371" ] }, "inpha_MonalizumabAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MonalizumabAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monalizumab Agreement", "verboseLabel": "of which monalizumab agreement - AstraZeneca", "label": "Monalizumab Agreement [Member]", "documentation": "This member stands for monalizumab agreement." } } }, "auth_ref": [] }, "inpha_MonalizumabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MonalizumabMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monalizumab", "label": "Monalizumab [Member]", "documentation": "This member stands for Monalizumab." } } }, "auth_ref": [] }, "inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement", "label": "Monalizumab Rights Under The 2014 Monalizumab (NKG2A) Novo Nordisk Agreement [Member]", "documentation": "This member stands for Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r379" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r352" ] }, "inpha_NetAmountsReceivablePayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NetAmountsReceivablePayableRelatedPartyTransactions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofTransactionsBetweenRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net receivables (liabilities)", "label": "Net Amounts Receivable (Payable) Related Party Transactions", "documentation": "The net amounts of receivables (payable) resulting from related party transactions." } } }, "auth_ref": [] }, "ifrs-full_NetForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign exchange gains", "label": "Net foreign exchange gain" } } }, "auth_ref": [ "r411", "r431" ] }, "ifrs-full_NetForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange losses", "label": "Net foreign exchange loss" } } }, "auth_ref": [ "r411", "r431" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "inpha_NonCancellableOffBalanceSheetPurchasedCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonCancellableOffBalanceSheetPurchasedCommitments", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cancellable off-balance sheet purchase commitments", "label": "Non Cancellable Off Balance Sheet Purchased Commitments", "documentation": "Represents the amount of non-cancellable off-balance sheet purchase commitments as of the specified date." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonCurrentFinancialAssetsAcquisitions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_TotalAcquisitions", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, acquisitions", "label": "Non-current Financial Assets, Acquisitions", "documentation": "The increase in non-current financial assets resulting from origination or purchase." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsForeignCurrencyEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonCurrentFinancialAssetsForeignCurrencyEffect", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_TotalForeignCurrencyEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, foreign currency effect", "label": "Non-current Financial Assets, Foreign Currency Effect", "documentation": "The increase (decrease) in non-current financial assets resulting from foreign exchange and other movements." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonCurrentFinancialAssetsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "label": "Non-current Financial Assets [Member]", "documentation": "This member stands for non-current financial assets." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, variation of fair value through the consolidated statement of income (loss)", "label": "Non-current Financial Assets, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)", "documentation": "The gains (losses) on non-current financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "inpha_NonCurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonCurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Non-Current Prepaid Expenses", "documentation": "Non-Current Prepaid Expenses" } } }, "auth_ref": [] }, "inpha_NonCurrentResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonCurrentResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research tax credit", "label": "Non-Current Research Tax Credit", "documentation": "The amount of non-current research tax credit." } } }, "auth_ref": [] }, "inpha_NonExecutivesBornAfter1968Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonExecutivesBornAfter1968Member", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-executives, born after 1968", "label": "Non-executives, Born After 1968 [Member]", "documentation": "Non-executives, Born After 1968" } } }, "auth_ref": [] }, "inpha_NonExecutivesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonExecutivesMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-executives", "label": "Non-executives [Member]", "documentation": "This member stands for non-executives." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r351" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r314", "r325", "r335", "r359", "r368" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r342" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r341" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r359" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r379" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r379" ] }, "inpha_NonScientificAdvisoryAndConsulting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NonScientificAdvisoryAndConsulting", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-scientific advisory and consulting", "label": "Non-scientific Advisory And Consulting", "documentation": "The amount of non-scientific advisory and consulting." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r61", "r225", "r259" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Non-current contract liabilities at beginning of period", "periodEndLabel": "Non-current contract liabilities at end of period", "label": "Non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r77" ] }, "ifrs-full_NoncurrentContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Current", "label": "Non-current contract liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue \u2013 non-current portion", "label": "Non-current deferred income including non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r433", "r436" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails": { "parentTag": "inpha_TotalCashCashEquivalentsAndFinancialAssets", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails", "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails", "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "periodStartLabel": "Beginning balance, non-current financial assets", "periodEndLabel": "Ending balance, non-current financial assets", "label": "Non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_NoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities \u2013 non-current portion", "label": "Non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r63", "r226", "r259" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPrepayments", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments made to suppliers", "label": "Non-current prepayments" } }, "en": { "role": { "documentation": "The amount of non-current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r281", "r287" ] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions \u2013 non-current portion", "label": "Non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit obligations", "label": "Non-current provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r204", "r229" ] }, "ifrs-full_NoncurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others - non-current", "totalLabel": "Receivables and others - non-current", "label": "Trade and other non-current receivables" } }, "en": { "role": { "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]" } } }, "auth_ref": [ "r203", "r216", "r228" ] }, "ifrs-full_NoncurrentReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other non-current receivables [abstract]" } } }, "auth_ref": [] }, "inpha_NontransferabilityPeriodOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NontransferabilityPeriodOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non transferability period (in years)", "label": "Nontransferability Period Other Equity Instruments Granted", "documentation": "The non-transferability period of other equity instruments granted." } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r85", "r86", "r90", "r135", "r138", "r223", "r270", "r275" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r429" ] }, "inpha_NovoNordiskASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NovoNordiskASMember", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails", "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novo Nordisk A/S", "label": "Novo Nordisk A/S [Member]", "documentation": "This member stands for Novo Nordisk A/S." } } }, "auth_ref": [] }, "inpha_NumberOfAdditionalTargets": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfAdditionalTargets", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional targets", "label": "Number Of Additional Targets", "documentation": "Number Of Additional Targets" } } }, "auth_ref": [] }, "inpha_NumberOfCohortsOfTheTrialThatDidNotMeetPrimaryEndpoints": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfCohortsOfTheTrialThatDidNotMeetPrimaryEndpoints", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of cohorts of the trial that did not meet primary endpoints", "label": "Number Of Cohorts Of The Trial That Did Not Meet Primary Endpoints", "documentation": "Number Of Cohorts Of The Trial That Did Not Meet Primary Endpoints" } } }, "auth_ref": [] }, "inpha_NumberOfCollaborationContracts": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfCollaborationContracts", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of collaboration contracts", "label": "Number Of Collaboration Contracts", "documentation": "Number Of Collaboration Contracts" } } }, "auth_ref": [] }, "inpha_NumberOfDirectors": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfDirectors", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of directors", "label": "Number Of Directors", "documentation": "Number Of Directors" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees", "label": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r429" ] }, "inpha_NumberOfEnvironmentalOrSocialActionsImplemented": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfEnvironmentalOrSocialActionsImplemented", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Implementation of environmental or social actions by employees", "label": "Number of Environmental or Social Actions Implemented", "documentation": "Number of Environmental or Social Actions Implemented" } } }, "auth_ref": [] }, "inpha_NumberOfExclusiveOptionsGranted": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfExclusiveOptionsGranted", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of exclusive options granted", "label": "Number Of Exclusive Options Granted", "documentation": "Number Of Exclusive Options Granted" } } }, "auth_ref": [] }, "inpha_NumberOfFilingAndApprovalOfABiologicLicenseApplication": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfFilingAndApprovalOfABiologicLicenseApplication", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of filing and approval of a biologic license application", "label": "Number Of Filing And Approval Of A Biologic License Application", "documentation": "Number of filing and approval of a biologic license application" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of free shares granted (in shares)", "verboseLabel": "Granted during the period", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r94", "r421" ] }, "inpha_NumberOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments with potential future dilutive effect not included in calculation of diluted earnings per share (in shares)", "label": "Number Of Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share", "documentation": "The number of instruments (including contingently issuable shares) that could potentially dilute basic earnings per share in the future, but were not included in the calculation of diluted earnings per share because they are antidilutive for the period(s) presented." } } }, "auth_ref": [] }, "inpha_NumberOfInternalConditionsPerformanceFreePerformanceShares": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfInternalConditionsPerformanceFreePerformanceShares", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of internal conditions performance, free performance shares", "label": "Number Of Internal Conditions Performance, Free Performance Shares", "documentation": "Number Of Internal Conditions Performance, Free Performance Shares" } } }, "auth_ref": [] }, "inpha_NumberOfLicensingAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfLicensingAgreements", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of licensing agreements", "label": "Number of Licensing Agreements", "documentation": "Number of Licensing Agreements" } } }, "auth_ref": [] }, "inpha_NumberOfLoans": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfLoans", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loans", "label": "Number Of Loans", "documentation": "Number Of Loans" } } }, "auth_ref": [] }, "inpha_NumberOfMembersOfTheSupervisoryBoardNotAppointedToTheBoardOfDirectors": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfMembersOfTheSupervisoryBoardNotAppointedToTheBoardOfDirectors", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of members of the supervisory board not appointed to the board of directors", "label": "Number Of Members Of The Supervisory Board Not Appointed To The Board Of Directors", "documentation": "Number Of Members Of The Supervisory Board Not Appointed To The Board Of Directors" } } }, "auth_ref": [] }, "inpha_NumberOfNewMembersAppointedToTheBoardOfDirectors": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfNewMembersAppointedToTheBoardOfDirectors", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of new members appointed to the board of directors", "label": "Number Of New Members Appointed To The Board Of Directors", "documentation": "Number Of New Members Appointed To The Board Of Directors" } } }, "auth_ref": [] }, "inpha_NumberOfOptionsExcercisedForLicenses": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfOptionsExcercisedForLicenses", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options excercised for licenses", "label": "Number of Options Excercised For Licenses", "documentation": "Number of Options Excercised For Licenses" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement (in shares)", "verboseLabel": "Number of other equity instruments exercisable in share-based payment arrangement (in shares)", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r421" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)", "negatedLabel": "Exercised during the period", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r421" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired during the period", "label": "Number of other equity instruments expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r421" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments forfeited in share-based payment arrangement (in shares)", "negatedLabel": "Forfeited during the period", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r421" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments outstanding in share-based payment arrangement (in shares)", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "verboseLabel": "Number of other equity instruments outstanding in share-based payment arrangement (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r421" ] }, "inpha_NumberOfPartnersSponsoringTrialCosts": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfPartnersSponsoringTrialCosts", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sponsor of trial", "label": "Number Of Partners Sponsoring Trial Costs", "documentation": "Number Of Partners Sponsoring Trial Costs" } } }, "auth_ref": [] }, "inpha_NumberOfPatientsPlannedToBeEnrolledInMedicalStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfPatientsPlannedToBeEnrolledInMedicalStudy", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patients planned to be enrolled in medical study", "label": "Number Of Patients Planned To Be Enrolled In Medical Study", "documentation": "Number Of Patients Planned To Be Enrolled In Medical Study" } } }, "auth_ref": [] }, "inpha_NumberOfPreclinicalMolecules": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfPreclinicalMolecules", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of preclinical molecules", "label": "Number Of Preclinical Molecules", "documentation": "Number Of Preclinical Molecules" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "terseLabel": "Total number of shares issued (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r426" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares outstanding (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r143", "r199", "r232" ] }, "inpha_NumberOfSpecifiedTargets": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfSpecifiedTargets", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of specified targets", "label": "Number Of Specified Targets", "documentation": "Specified targets" } } }, "auth_ref": [] }, "inpha_NumberOfTherapeuticApproaches": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfTherapeuticApproaches", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of therapeutic approaches", "label": "Number Of Therapeutic Approaches", "documentation": "Number Of Therapeutic Approaches" } } }, "auth_ref": [] }, "inpha_NumberOfVestingKickers": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfVestingKickers", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of vesting kickers", "label": "Number Of Vesting Kickers", "documentation": "Number Of Vesting Kickers" } } }, "auth_ref": [] }, "inpha_NumberOfVotingRightsHeld": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfVotingRightsHeld", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of voting rights held (in shares)", "label": "Number Of Voting Rights Held", "documentation": "Number Of Voting Rights Held" } } }, "auth_ref": [] }, "inpha_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of subsidiaries", "label": "Number Of Wholly Owned Subsidiaries", "documentation": "Number Of Wholly Owned Subsidiaries" } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment and office furniture", "label": "Office equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opening balance before adjustment, cumulative effect at date of initial application", "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]" } } }, "auth_ref": [ "r427" ] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "label": "Operating expense" } } }, "auth_ref": [ "r438" ] }, "inpha_OperatingExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OperatingExpenseAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expense [Abstract]", "documentation": "Operating Expense" } } }, "auth_ref": [] }, "inpha_OptionExerciseFeePayableByCounterParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OptionExerciseFeePayableByCounterParty", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option exercise fee payable by counter party", "label": "Option Exercise Fee Payable By Counter Party", "documentation": "The amount of option exercise fee payable by the counter party." } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r437" ] }, "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsToReconcileProfitLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other profit or loss items with no cash effect", "label": "Other adjustments to reconcile profit (loss)" } } }, "auth_ref": [ "r47" ] }, "inpha_OtherAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other Agreement [Member]", "documentation": "This member stands for other agreement." } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "label": "Other comprehensive income" } } }, "auth_ref": [ "r67", "r211", "r236", "r241" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation gain (loss)", "verboseLabel": "Foreign currency translation (loss) gain", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r227", "r241" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of short-term investments and non-current financial assets", "label": "Other comprehensive income, net of tax, financial assets measured at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to financial assets measured at fair value through other comprehensive income applying paragraph 4.1.2A of IFRS 9. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]" } } }, "auth_ref": [ "r227", "r241" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains and (losses) related to defined benefit obligations", "verboseLabel": "Actuarial (losses) gains on defined benefit obligations", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r227", "r241", "r406" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other payables", "label": "Other current payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r433" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r281", "r287" ] }, "inpha_OtherCurrentTaxCreditsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherCurrentTaxCreditsReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other tax credits", "label": "Other Current Tax Credits Receivables", "documentation": "The amount of other current tax credits receivables." } } }, "auth_ref": [] }, "inpha_OtherEquityInstrumentsPerformanceConditionsThreshold": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherEquityInstrumentsPerformanceConditionsThreshold", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance conditions threshold", "label": "Other Equity Instruments, Performance Conditions Threshold", "documentation": "Other Equity Instruments, Performance Conditions Threshold" } } }, "auth_ref": [] }, "inpha_OtherFinancialExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherFinancialExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other financial expenses", "label": "Other Financial Expenses", "documentation": "The amount of other financial expenses." } } }, "auth_ref": [] }, "inpha_OtherFinancialIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherFinancialIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other financial income", "label": "Other Financial Income", "documentation": "The amount of other financial income." } } }, "auth_ref": [] }, "inpha_OtherFreeSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherFreeSharesMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other free shares", "label": "Other Free Shares [Member]", "documentation": "Other Free Shares" } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other income" } } }, "auth_ref": [ "r27", "r283", "r284" ] }, "inpha_OtherIndividualShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherIndividualShareholdersMember", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public", "label": "Other Individual Shareholders [Member]", "documentation": "Other Individual Shareholders" } } }, "auth_ref": [] }, "ifrs-full_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Other intangible assets [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r415" ] }, "inpha_OtherLongTermBenefitsYearsOfServiceThresholdOne": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherLongTermBenefitsYearsOfServiceThresholdOne", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long term benefits, years of service, threshold one", "label": "Other Long Term Benefits, Years Of Service, Threshold One", "documentation": "Other Long Term Benefits, Years Of Service, Threshold One" } } }, "auth_ref": [] }, "inpha_OtherLongTermBenefitsYearsOfServiceThresholdThree": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherLongTermBenefitsYearsOfServiceThresholdThree", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long term benefits, years of service, threshold three", "label": "Other Long Term Benefits, Years Of Service, Threshold Three", "documentation": "Other Long Term Benefits, Years Of Service, Threshold Three" } } }, "auth_ref": [] }, "inpha_OtherLongTermBenefitsYearsOfServiceThresholdTwo": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherLongTermBenefitsYearsOfServiceThresholdTwo", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long term benefits, years of service, threshold two", "label": "Other Long Term Benefits, Years Of Service, Threshold Two", "documentation": "Other Long Term Benefits, Years Of Service, Threshold Two" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentNonfinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other non-current non-financial assets" } }, "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r433" ] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income and (expenses), net", "label": "Other operating income (expense)" } } }, "auth_ref": [ "r438" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r351" ] }, "inpha_OtherProductAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherProductAndServicesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other Product And Services [Member]", "documentation": "Other Product And Services" } } }, "auth_ref": [] }, "inpha_OtherPurchasesAndExternalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherPurchasesAndExternalExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other purchases and external expenses", "label": "Other Purchases And External Expenses", "documentation": "The amount of other purchases and external expenses." } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Other reserves", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r282", "r288" ] }, "ifrs-full_OtherReservesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReservesMember", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other reserves", "label": "Other reserves [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r146", "r213" ] }, "inpha_OtherRevenueReinvoicingExternalExpensesUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "OtherRevenueReinvoicingExternalExpensesUnderAgreement", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue, reinvoicing external expenses under agreement", "label": "Other Revenue, Reinvoicing External Expenses Under Agreement", "documentation": "Other Revenue, Reinvoicing External Expenses Under Agreement" } } }, "auth_ref": [] }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Others differences", "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r2", "r152" ] }, "ifrs-full_OtherTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTemporaryDifferencesMember", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other temporary differences", "label": "Other temporary differences [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r403" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r312", "r323", "r333", "r366" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r315", "r326", "r336", "r369" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r315", "r326", "r336", "r369" ] }, "inpha_PGELoanAgreementAccruedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PGELoanAgreementAccruedInterestMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State guaranteed loans - accrued interest", "label": "PGE Loan Agreement, Accrued Interest [Member]", "documentation": "PGE Loan Agreement, Accrued Interest" } } }, "auth_ref": [] }, "inpha_PGELoanAgreementBNPParibasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PGELoanAgreementBNPParibasMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State guaranteed loan BNP Paribas", "terseLabel": "PGE loan agreement, BNP Paribas", "label": "PGE Loan Agreement, BNP Paribas [Member]", "documentation": "PGE Loan Agreement, BNP Paribas" } } }, "auth_ref": [] }, "inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PGELoanAgreementSocieteGeneraleAndBNPParibasMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PGE loan agreement, Societe Generale and BNP Paribas", "label": "PGE Loan Agreement, Societe Generale And BNP Paribas [Member]", "documentation": "PGE Loan Agreement, Societe Generale And BNP Paribas" } } }, "auth_ref": [] }, "inpha_PGELoanAgreementSocieteGeneraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PGELoanAgreementSocieteGeneraleMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforNonDerivativeFinancialLiabilitiesDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofSchedulefortheContractualFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State guaranteed loan Soci\u00e9t\u00e9 G\u00e9n\u00e9rale", "terseLabel": "PGE loan agreement, Societe Generale", "label": "PGE Loan Agreement, Societe Generale [Member]", "documentation": "PGE Loan Agreement, Societe Generale" } } }, "auth_ref": [] }, "inpha_PH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S", "label": "PH5401 (Anti-C5aR) Rights Acquired From Novo Nordisk A/S [Member]", "documentation": "This member stands for PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S." } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share (in EUR per share)", "verboseLabel": "Nominal value (in EUR per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r142", "r198", "r231" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r340" ] }, "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Tax and employee-related payables", "label": "Payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } } }, "auth_ref": [ "r436" ] }, "inpha_PaymentsForMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PaymentsForMilestone", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for milestone", "label": "Payments For Milestone", "documentation": "Represents payments for milestone." } } }, "auth_ref": [] }, "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments (benefits and contributions paid by the employer)", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r14", "r163" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r350" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r350" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r342" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r359" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r352" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r341" ] }, "inpha_PercentOfEmployeesUsingTransportMobility": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentOfEmployeesUsingTransportMobility", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of employees using transport mobility", "label": "Percent Of Employees Using Transport Mobility", "documentation": "Percent Of Employees Using Transport Mobility" } } }, "auth_ref": [] }, "inpha_PercentageOfAnnualVariableCompensation": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfAnnualVariableCompensation", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentge of annual variable compensation", "label": "Percentage Of Annual Variable Compensation", "documentation": "The percentage of annual variable compensation." } } }, "auth_ref": [] }, "inpha_PercentageOfOverPerformance": { "xbrltype": "pureItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfOverPerformance", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of over performance", "label": "Percentage Of Over Performance", "documentation": "Percentage Of Over Performance" } } }, "auth_ref": [] }, "inpha_PercentageOfPaymentsInUSDollars": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfPaymentsInUSDollars", "presentation": [ "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of payments in US dollars", "label": "Percentage Of Payments In US Dollars", "documentation": "The percentage of payments in US dollars." } } }, "auth_ref": [] }, "inpha_PercentageOfPreFinancedCIRCollected": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfPreFinancedCIRCollected", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of nominal value deconsolidated receivables, CIR 2023", "label": "Percentage of Pre-Financed CIR Collected", "documentation": "Percentage of Pre-Financed CIR Collected" } } }, "auth_ref": [] }, "inpha_PercentageOfPremiumIncreased": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfPremiumIncreased", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of premium increased", "label": "Percentage Of Premium Increased", "documentation": "The percentage of premium increased." } } }, "auth_ref": [] }, "inpha_PercentageOfProfitsInEurope": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfProfitsInEurope", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of profits in Europe", "label": "Percentage Of Profits In Europe", "documentation": "The percentage of profits in Europe." } } }, "auth_ref": [] }, "inpha_PercentageOfRevenueDenominatedInUSDollars": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfRevenueDenominatedInUSDollars", "presentation": [ "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of revenue denominated in US dollars", "label": "Percentage Of Revenue Denominated In US Dollars", "documentation": "The percentage of revenue that denominated in US dollars." } } }, "auth_ref": [] }, "inpha_PercentageOfShareholdingInTheCompany": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PercentageOfShareholdingInTheCompany", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails", "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shareholding in the company", "label": "Percentage of Shareholding In The Company", "documentation": "Percentage of Shareholding In The Company" } } }, "auth_ref": [] }, "inpha_PeriodOfBirthAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PeriodOfBirthAxis", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of Birth [Axis]", "label": "Period of Birth [Axis]", "documentation": "Period of Birth" } } }, "auth_ref": [] }, "inpha_PeriodOfBirthDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PeriodOfBirthDomain", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of Birth [Domain]", "label": "Period of Birth [Domain]", "documentation": "Period of Birth [Domain]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r343" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r399" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment benefit expense, defined contribution plans", "label": "Post-employment benefit expense, defined contribution plans" } } }, "auth_ref": [ "r15", "r159" ] }, "inpha_PotentialAdditionalMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PotentialAdditionalMilestonePayments", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential additional milestone payments", "label": "Potential Additional Milestone Payments", "documentation": "Potential Additional Milestone Payments" } } }, "auth_ref": [] }, "inpha_PreclinicalMoleculesAgreementWithAstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PreclinicalMoleculesAgreementWithAstraZenecaMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "of which preclinical molecules agreement - AstraZeneca", "label": "Preclinical Molecules Agreement With AstraZeneca [Member]", "documentation": "Preclinical Molecules Agreement With AstraZeneca" } } }, "auth_ref": [] }, "inpha_PreclinicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PreclinicalServicesMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preclinical Services", "label": "Preclinical Services [Member]", "documentation": "Preclinical Services" } } }, "auth_ref": [] }, "ifrs-full_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreferenceSharesMember", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares", "label": "Preference shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r437" ] }, "inpha_PriceWaterhouseCooperPWCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PriceWaterhouseCooperPWCMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PwC", "label": "Price Waterhouse Cooper (PWC) [Member]", "documentation": "Price Waterhouse Cooper (PWC)" } } }, "auth_ref": [] }, "inpha_PricewaterhouseCoopersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PricewaterhouseCoopersMember", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "PricewaterhouseCoopers", "label": "PricewaterhouseCoopers [Member]", "documentation": "PricewaterhouseCoopers" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r256" ] }, "inpha_ProceedsFromExerciseOfOptionAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ProceedsFromExerciseOfOptionAgreement", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of option agreement", "label": "Proceeds From Exercise Of Option Agreement", "documentation": "The cash inflow from the exercise of option agreement." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the exercise / subscription of equity instruments", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r255" ] }, "inpha_ProceedsFromLeaseLiabilitiesAndOtherNonCashEffectsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ProceedsFromLeaseLiabilitiesAndOtherNonCashEffectsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non cash effects : proceeds from lease liabilities and other", "label": "Proceeds From Lease Liabilities And Other Non Cash Effects, Classified As Financing Activities", "documentation": "The amount of proceeds from lease liabilities." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of other assets", "label": "Proceeds from sales of other long-term assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of property and equipment", "label": "Proceeds from sales of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r254" ] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services [axis]", "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r125", "r263", "r278" ] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services", "label": "Products and services [domain]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r125", "r263", "r278" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 11.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows", "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/IncomelosspershareSummaryofIncomeLossperShareDetails", "http://www.innate-pharma.com/role/ThecompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss) for the period", "terseLabel": "Net income (loss)", "netLabel": "Net loss", "negatedLabel": "Net loss for the period", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r57", "r59", "r120", "r122", "r170", "r183", "r210", "r235", "r259", "r266" ] }, "ifrs-full_ProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAbstract", "lang": { "en-us": { "role": { "terseLabel": "Profit (loss) [abstract]", "label": "Profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) before tax", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r96", "r276", "r277", "r283", "r284" ] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) from continuing operations", "label": "Profit (loss) from continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]" } } }, "auth_ref": [ "r66", "r120", "r122", "r235" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r249", "r438" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment [abstract]", "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "inpha_PropertyPlantAndEquipmentExcludingRightOfUseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "PropertyPlantAndEquipmentExcludingRightOfUseAssetsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subtotal (excluding RoU)", "label": "Property Plant And Equipment Excluding Right Of Use Assets [Member]", "documentation": "Property Plant And Equipment Excluding Right Of Use Assets" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "periodStartLabel": "Property, plant and equipment including right-of-use assets at beginning of period", "periodEndLabel": "Property, plant and equipment including right-of-use assets at end of period", "label": "Property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r84", "r405", "r432" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [axis]", "label": "Property, plant and equipment including right-of-use assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r405" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [domain]", "label": "Property, plant and equipment including right-of-use assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a class of asset representing property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r405" ] }, "inpha_ProportionOfVotingRightsHeldInTheCompany": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ProportionOfVotingRightsHeldInTheCompany", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of voting rights held in the company", "label": "Proportion Of Voting Rights Held In The Company", "documentation": "Proportion Of Voting Rights Held In The Company" } } }, "auth_ref": [] }, "inpha_ProvisionForAttendanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ProvisionForAttendanceFees", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for attendance fees", "label": "Provision For Attendance Fees", "documentation": "The amount of provision for attendance fees." } } }, "auth_ref": [] }, "inpha_ProvisionForDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ProvisionForDefinedBenefitObligationMember", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Provision for defined benefit obligation", "label": "Provision for defined benefit obligation [Member]", "documentation": "Provision for defined benefit obligation" } } }, "auth_ref": [] }, "ifrs-full_Provisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Provisions", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Provisions" } }, "en": { "role": { "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits." } } }, "auth_ref": [ "r219" ] }, "ifrs-full_ProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionsForEmployeeBenefits", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions for employee benefits", "label": "Provisions for employee benefits" } } }, "auth_ref": [ "r204", "r229" ] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of intangible assets", "terseLabel": "Purchase of intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of other assets", "label": "Purchase of other long-term assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of property and equipment, net", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r253" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r340" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r340" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r52", "r76", "r89", "r92", "r147", "r260", "r261", "r423" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [domain]", "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r52", "r76", "r89", "r92", "r147", "r260", "r261", "r423" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_RawMaterialsAndConsumablesUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RawMaterialsAndConsumablesUsed", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalInformationDetails", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of supplies and consumable materials", "terseLabel": "Raw materials and consumables used", "label": "Raw materials and consumables used" } } }, "auth_ref": [ "r243", "r283" ] }, "inpha_ReceiptsFromCodevelopmentAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ReceiptsFromCodevelopmentAgreement", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts from co-development agreement", "label": "Receipts From Codevelopment Agreement", "documentation": "The cash inflow from co-development agreement." } } }, "auth_ref": [] }, "inpha_ReceiptsFromCodevelopmentAgreementAndOptionAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ReceiptsFromCodevelopmentAgreementAndOptionAgreement", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts from co-development agreement and option agreement", "label": "Receipts From Codevelopment Agreement And Option Agreement", "documentation": "The cash inflow from co-development agreement and option agreement." } } }, "auth_ref": [] }, "inpha_ReceiptsFromOptionAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ReceiptsFromOptionAgreement", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts from option agreement", "label": "Receipts From Option Agreement", "documentation": "The cash inflow from option agreement." } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]", "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r307", "r318", "r328", "r361" ] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related party transactions [abstract]", "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "inpha_RepaymentsOfBorrowingsAndLeaseLiabilitiesNetOfExchangeRateVariationClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RepaymentsOfBorrowingsAndLeaseLiabilitiesNetOfExchangeRateVariationClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of borrowings and lease liabilities", "label": "Repayments Of Borrowings And Lease Liabilities, Net Of Exchange Rate Variation, Classified As Financing Activities", "documentation": "Repayments Of Borrowings And Lease Liabilities, Net Of Exchange Rate Variation, Classified As Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of borrowings", "label": "Repayments of borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r257" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.innate-pharma.com/role/AuditInformation", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofAuditandNonAuditFeesDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "label": "Research and development expense" } } }, "auth_ref": [ "r44", "r181" ] }, "inpha_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D", "label": "Research And Development [Member]", "documentation": "Research And Development" } } }, "auth_ref": [] }, "inpha_ResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ResearchTaxCredit", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Research Tax Credit", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to research tax credit." } } }, "auth_ref": [] }, "inpha_ResearchTaxCreditReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ResearchTaxCreditReceivableCurrent", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research tax credit", "label": "Research Tax Credit, Receivable, Current", "documentation": "The amount of current research tax credits." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r308", "r319", "r329", "r362" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r309", "r320", "r330", "r363" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r316", "r327", "r337", "r370" ] }, "ifrs-full_RestructuringProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestructuringProvisionMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring provision", "label": "Restructuring provision [member]" } }, "en": { "role": { "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Classes of other provisions [domain]]" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained earnings, excluding profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r435" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained earnings, excluding profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit, excluding profit or loss for the reporting period. [Refer: Retained earnings [member]]" } } }, "auth_ref": [ "r428" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Retained earnings, profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r435" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Retained earnings, profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r428" ] }, "inpha_RetirementDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RetirementDefinedBenefitMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofActuarialAssumptionsforDefinedBenefitPlansDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for retirement defined benefit", "label": "Retirement Defined Benefit [Member]", "documentation": "This member stands for retirement defined benefit." } } }, "auth_ref": [] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue and other income", "label": "Revenue" } } }, "auth_ref": [ "r65", "r96", "r116", "r121", "r125", "r126", "r128", "r238", "r259", "r283", "r284" ] }, "inpha_RevenueAndOtherIncome": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueAndOtherIncome", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and other income", "label": "Revenue And Other Income" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaboration and licensing agreements", "verboseLabel": "Revenue from collaboration and licensing agreements", "label": "Revenue from contracts with customers" } } }, "auth_ref": [ "r78", "r79", "r132" ] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceived", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance received", "label": "Revenue From Contracts With Customers, Advance Payment Received", "documentation": "The amount of advance received by the company." } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance received - exclusive license", "label": "Revenue From Contracts With Customers, Advance Payment Received, Licenses", "documentation": "Revenue From Contracts With Customers, Advance Payment Received, Licenses" } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance received - research work", "label": "Revenue From Contracts With Customers, Advance Payment Received, Research", "documentation": "Revenue From Contracts With Customers, Advance Payment Received, Research" } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance received - additional targets", "label": "Revenue From Contracts With Customers, Advance Payment Received, Target Options", "documentation": "Revenue From Contracts With Customers, Advance Payment Received, Target Options" } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersExerciseOfOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersExerciseOfOption", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of option", "label": "Revenue From Contracts With Customers, Exercise Of Option", "documentation": "The amount of revenue from contracts with customer recognized by exercise of option." } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersFavorableCumulativeAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersFavorableCumulativeAdjustment", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from favorable cumulative adjustment", "label": "Revenue From Contracts With Customers, Favorable Cumulative Adjustment", "documentation": "The amount of favorable cumulative adjustment to revenue." } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersInitialPayment", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial payment", "label": "Revenue From Contracts With Customers, Initial Payment", "documentation": "The amount of initial payment pursuant to the agreement." } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersMilestonePaymentReceived", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment received", "label": "Revenue From Contracts With Customers, Milestone Payment Received", "documentation": "Revenue From Contracts With Customers, Milestone Payment Received" } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment received - option exercised", "label": "Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised", "documentation": "Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofGovernmentFinancingforResearchExpendituresDetails": { "parentTag": "inpha_GovernmentFinancingForResearchExpenditures", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofGovernmentFinancingforResearchExpendituresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Grant and other tax credit", "label": "Income from government grants" } } }, "auth_ref": [ "r410" ] }, "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill" } } }, "auth_ref": [ "r40", "r177" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r83" ] }, "inpha_RiskFreeInterestRateOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Risk Free Interest Rate Other Equity Instruments Granted", "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for other equity instruments granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise)." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r379" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r379" ] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Marketing, communication and public relations", "label": "Sales and marketing expense" } } }, "auth_ref": [ "r438" ] }, "inpha_SanofiAventisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SanofiAventisMember", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi-Aventis", "label": "Sanofi-Aventis [Member]", "documentation": "Sanofi-Aventis" } } }, "auth_ref": [] }, "inpha_SanofiAventisParticipationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SanofiAventisParticipationsMember", "presentation": [ "http://www.innate-pharma.com/role/TheCompanySummaryofthecompanysshareholdinginformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi-Aventis Participations", "label": "Sanofi-Aventis Participations [Member]", "documentation": "Sanofi-Aventis Participations" } } }, "auth_ref": [] }, "inpha_SanofiOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SanofiOptionsMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi options", "label": "Sanofi Options [Member]", "documentation": "Sanofi Options" } } }, "auth_ref": [] }, "inpha_SanofiServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SanofiServicesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi services", "label": "Sanofi Services [Member]", "documentation": "Sanofi Services" } } }, "auth_ref": [] }, "inpha_ScientificAdvisoryAndConsulting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ScientificAdvisoryAndConsulting", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Scientific advisory and consulting", "label": "Scientific Advisory And Consulting", "documentation": "The amount of Scientific advisory and consulting." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r290" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r292" ] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsReleased", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments released", "label": "Security Interest On Pledge Of Financial Instruments Released", "documentation": "Security Interest On Pledge Of Financial Instruments Released" } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments will be released in 2024", "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2024", "documentation": "The values of security interest on the pledge of financial instruments will be released in 2024." } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments will be released in 2027", "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2027", "documentation": "The values of security interest on pledge of financial instruments will be released in 2027." } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments will be released in 2031", "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2031", "documentation": "The values of Security interest on pledge of financial instruments will be released in 2024." } } }, "auth_ref": [] }, "inpha_SeniorityAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SeniorityAwardsMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitsAdditionalInformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitsDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for seniority awards", "label": "Seniority Awards [Member]", "documentation": "This member stands for seniority awards." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "inpha_ShareBasedPaymentTransactionsWithEmployeesAwardsExpectedTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShareBasedPaymentTransactionsWithEmployeesAwardsExpectedTerm", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment transactions with employees, awards, expected term (year)", "label": "Share-based Payment Transactions With Employees Awards Expected Term", "documentation": "The expected term of awards granted in a share-based payment transactions." } } }, "auth_ref": [] }, "inpha_ShareCapitalAndShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShareCapitalAndShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share Capital And Share Based Payments [Abstract]", "label": "Share Capital And Share Based Payments [Abstract]" } } }, "auth_ref": [] }, "inpha_ShareEntitlementPerFreeShareOtherEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShareEntitlementPerFreeShareOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share entitlement per free share (in shares)", "label": "Share Entitlement Per Free Share Other Equity Instruments Granted", "documentation": "The share entitlement per free share of other equity instruments granted." } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share issue related cost", "label": "Share issue related cost" } } }, "auth_ref": [ "r426" ] }, "inpha_ShareIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShareIssuedPricePerShare", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share issued, price per share (in EUR per share)", "label": "Share Issued Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r282", "r288" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of own shares (in shares)", "label": "Number of shares in entity held by entity or by its subsidiaries or associates" } }, "en": { "role": { "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r144", "r200", "r233" ] }, "inpha_SharesIssuedForTheAcquisitionOfC5aRIntangibleAssetInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SharesIssuedForTheAcquisitionOfC5aRIntangibleAssetInShares", "presentation": [ "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for the acquisition of C5aR intangible asset (in shares)", "label": "Shares Issued For The Acquisition Of C5aR Intangible Asset (In Shares)", "documentation": "The increase (decrease) in the number of shares issued resulting from the acquisition of licenses." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShortTermInvestmentMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-term Investment [Member]", "documentation": "This member stands for short-term investments." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShortTermInvestmentsAcquisitions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_TotalAcquisitions", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, acquisitions", "label": "Short-term Investments, Acquisitions", "documentation": "The increase in current investment resulting from origination or purchase." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShortTermInvestmentsAndNonCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, total", "periodEndLabel": "Ending balance, total", "label": "Short-term Investments And Non-current Financial Assets", "documentation": "The amount of short-term investments and non-current financial assets." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsForeignCurrencyEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShortTermInvestmentsForeignCurrencyEffect", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_TotalForeignCurrencyEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, foreign currency effect", "label": "Short-term Investments, Foreign Currency Effect", "documentation": "The increase (decrease) in current financial assets resulting from foreign exchange and other movements." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, variation of fair value through the consolidated statement of income (loss)", "label": "Short-term Investments, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)", "documentation": "The gains (losses) on current financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalInformationDetails", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Personnel expenses other than share-based compensation", "terseLabel": "Personnel expenses other than share-based compensation", "label": "Short-term employee benefits expense" } } }, "auth_ref": [ "r429" ] }, "inpha_SignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Abstract]", "label": "Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "inpha_StateGuaranteedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "StateGuaranteedLoansMember", "presentation": [ "http://www.innate-pharma.com/role/ManagementoffinancialrisksandfairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State guaranteed loans", "label": "State Guaranteed Loans [Member]", "documentation": "State Guaranteed Loans" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of cash flows [abstract]", "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [abstract]", "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of comprehensive income [abstract]", "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of financial position [abstract]", "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "srt_StatisticalDisclosureForBanksAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatisticalDisclosureForBanksAbstract", "lang": { "en-us": { "role": { "label": "Statistical Disclosure for Banks [Abstract]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r311", "r322", "r332", "r365" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "inpha_StockOptions20201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "StockOptions20201Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options 2020-1", "label": "Stock Options 2020-1 [Member]", "documentation": "Stock Options 2020-1" } } }, "auth_ref": [] }, "inpha_StockOptions2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "StockOptions2024Member", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options 2024-1", "verboseLabel": "Stock-option 2024", "label": "Stock Options 2024 [Member]", "documentation": "Stock Options 2024" } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]", "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "inpha_SubcontractingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SubcontractingCosts", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Subcontracting costs", "label": "Subcontracting Costs", "documentation": "The amount of subcontracting costs." } } }, "auth_ref": [] }, "inpha_SubscriptionOfShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SubscriptionOfShareWarrantsMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsciption of share warrants", "label": "Subscription Of Share Warrants [Member]", "documentation": "Subscription Of Share Warrants" } } }, "auth_ref": [] }, "inpha_SummaryOfChangesInWorkingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "SummaryOfChangesInWorkingCapitalAbstract", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of changes in working capital [abstract]", "label": "Summary Of Changes In Working Capital [Abstract]", "documentation": "Summary Of Changes In Working Capital" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r358" ] }, "inpha_TaxAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxAmortizationMember", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax amortization", "label": "Tax Amortization [Member]", "documentation": "Tax Amortization" } } }, "auth_ref": [] }, "inpha_TaxCreditRetentions2024CIR": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxCreditRetentions2024CIR", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit retentions 2024, CIR", "label": "Tax Credit Retentions 2024, CIR", "documentation": "Tax Credit Retentions 2024, CIR" } } }, "auth_ref": [] }, "inpha_TaxCreditRetentions2025CIR": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxCreditRetentions2025CIR", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit retentions 2025, CIR", "label": "Tax Credit Retentions 2025, CIR", "documentation": "Tax Credit Retentions 2025, CIR" } } }, "auth_ref": [] }, "inpha_TaxCreditRetentionsCIR": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxCreditRetentionsCIR", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapitalAdjusted", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "5% retained - Tax credit refund", "label": "Tax Credit Retentions, CIR", "documentation": "Tax Credit Retentions, CIR" } } }, "auth_ref": [] }, "inpha_TaxEffectOfCarryBack": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxEffectOfCarryBack", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carry-back", "label": "Carry-back", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to carry-back." } } }, "auth_ref": [] }, "inpha_TaxEffectOfDefinedBenefitObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxEffectOfDefinedBenefitObligations", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision for defined benefit obligations", "label": "Tax Effect Of Defined Benefit Obligations", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to defined benefit obligations." } } }, "auth_ref": [] }, "inpha_TaxEffectOfExerciseOfRealEstateLeasingOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxEffectOfExerciseOfRealEstateLeasingOption", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impact linked to the exercise of a real estate leasing option", "label": "Tax Effect Of Exercise Of Real Estate Leasing Option", "documentation": "Tax Effect Of Exercise Of Real Estate Leasing Option" } } }, "auth_ref": [] }, "inpha_TaxEffectOfIntraGroupMergerOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxEffectOfIntraGroupMergerOperations", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impact linked to intra-group merger operations", "label": "Tax Effect Of Intra-Group Merger Operations", "documentation": "Tax Effect Of Intra-Group Merger Operations" } } }, "auth_ref": [] }, "inpha_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-recognition of deferred tax assets related to tax losses and temporary differences", "label": "Tax Effect Of Non-recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of deferred tax assets related to tax losses and temporary differences." } } }, "auth_ref": [] }, "inpha_TaxEffectOfRevenueFromCollaborationsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxEffectOfRevenueFromCollaborationsWithCustomers", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Revenue from collaboration agreements", "label": "Tax Effect Of Revenue From Collaborations With Customers", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to revenue from collaborations with customers." } } }, "auth_ref": [] }, "inpha_TaxEffectOfShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TaxEffectOfShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Share-based compensation", "label": "Tax Effect Of Share-based Compensation", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share-based compensation." } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails": { "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit / (expense) calculated at statutory tax rate", "label": "Tax expense (income) at applicable tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r2", "r152" ] }, "inpha_TechnicalInstallationsAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TechnicalInstallationsAndEquipmentMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technical installations and equipment", "label": "Technical Installations And Equipment [Member]", "documentation": "This member stands for technical installations and equipment." } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r156" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits", "label": "Temporary difference, unused tax losses and unused tax credits [domain]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r156" ] }, "inpha_TerminationNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TerminationNoticePeriod", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination notice period (in days)", "label": "Termination Notice Period", "documentation": "Termination Notice Period" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r52", "r76", "r89", "r92", "r147", "r260", "r261", "r423" ] }, "inpha_TotalAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TotalAcquisitions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, acquisitions", "label": "Total, Acquisitions", "documentation": "The increase in short-term investments and non-current financial assets resulting from origination or purchase." } } }, "auth_ref": [] }, "inpha_TotalCashCashEquivalentsAndFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TotalCashCashEquivalentsAndFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofCashCashEquivalentsandFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents and financial assets", "terseLabel": "Cash, cash equivalents and financial assets", "label": "Total Cash, Cash Equivalents And Financial Assets", "documentation": "The amount of cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "inpha_TotalForeignCurrencyEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TotalForeignCurrencyEffect", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, foreign currency effect", "label": "Total, Foreign Currency Effect", "documentation": "The increase (decrease) in short-term and non-current financial assets resulting from foreign exchange and other movements." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r350" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r357" ] }, "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsandfinancialassetsDisclosureofReconciliationofChangesinLossAllowanceandExplanationofChangesinGrossCarryingAmountforFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, variation of fair value through the consolidated statement of income (loss)", "label": "Total, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)", "documentation": "The gains (losses) on short-term investment and non-current financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others", "totalLabel": "Payables and others", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r218" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Suppliers (excluding payables related to capital expenditures)", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r286", "r436" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others - current", "totalLabel": "Receivables and others - current", "label": "Trade and other current receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r203", "r216", "r228" ] }, "ifrs-full_TradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayables", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade payables and others (excluding payables related to capital expenditures)", "label": "Trade and other payables" } }, "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } } }, "auth_ref": [ "r218" ] }, "ifrs-full_TradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": -1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlows", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others (excluding rebates related to capital expenditures)", "totalLabel": "Trade receivables and others", "label": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r203", "r216", "r228" ] }, "inpha_TradePayablesAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TradePayablesAndOthersMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others", "label": "Trade Payables And Others [Member]", "documentation": "This member stands for trade payables and others." } } }, "auth_ref": [] }, "inpha_TradeReceivablesAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TradeReceivablesAndOthersMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others", "label": "Trade Receivables And Others [Member]", "documentation": "This member stands for trade receivables and others." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r378" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r380" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "inpha_TransferFromToCollaborationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TransferFromToCollaborationLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofVarianceofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transfer from collaboration liabilities", "terseLabel": "Transfer from collaboration liabilities", "label": "Transfer From (To) Collaboration Liabilities", "documentation": "The decrease in contract liabilities resulting from transfer to collaboration liabilities." } } }, "auth_ref": [] }, "ifrs-full_TravelExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TravelExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofExpensesbyNatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Travel expenses and meeting attendance", "label": "Travel expense" } } }, "auth_ref": [ "r429" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r381" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r382" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r382" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r380" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r380" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r383" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r381" ] }, "inpha_TypeOfExerciseAndSubscriptionOfSharesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TypeOfExerciseAndSubscriptionOfSharesAxis", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Exercise And Subscription Of Shares [Axis]", "label": "Type of Exercise And Subscription Of Shares [Axis]", "documentation": "Type of Exercise And Subscription Of Shares" } } }, "auth_ref": [] }, "inpha_TypeOfExerciseAndSubscriptionOfSharesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "TypeOfExerciseAndSubscriptionOfSharesDomain", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Exercise And Subscription Of Shares [Domain]", "label": "Type of Exercise And Subscription Of Shares [Domain]", "documentation": "Type of Exercise And Subscription Of Shares [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails", "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [axis]", "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r265", "r267", "r280" ] }, "ifrs-full_TypesOfContractsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsDomain", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails", "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationsDetails", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalInformationDetails", "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofDetailedInformationaboutIntangibleAssetsDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresAdditionalInformationDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofChangesinDeferredRevenueandCollaborationLiabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandgovernmentfinancingforresearchexpendituresDisclosureofRevenuefromCollaborationandLicensingAgreementsDetails", "http://www.innate-pharma.com/role/Thecompany2014NovoNordiskASmonalizumabagreementDetails", "http://www.innate-pharma.com/role/Thecompany2015AstraZenecamonalizumabagreementsDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoIPH5201withAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementrelatedtoadditionalpreclinicalmoleculeswithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails", "http://www.innate-pharma.com/role/ThecompanyCollaborationandlicenseagreementsconcludedwithSanofiforthedevelopmentofNKCellengagesinoncologyDetails", "http://www.innate-pharma.com/role/ThecompanyKeyeventsDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts", "label": "Types of contracts [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r265", "r267", "r280" ] }, "ifrs-full_TypesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfFinancialAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of financial assets [axis]", "label": "Types of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r113", "r114" ] }, "ifrs-full_TypesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfFinancialAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofFinancialLiabilitiesPerMaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of financial assets", "label": "Types of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated types of financial assets. It also represents the standard value for the 'Types of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r113", "r114" ] }, "ifrs-full_TypesOfInterestRatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates [axis]", "label": "Types of interest rates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r422" ] }, "ifrs-full_TypesOfInterestRatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates", "label": "Types of interest rates [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r422" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r93", "r184" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsAdditionalInformationDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofBreakdownofExpensesperFinancialYearDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofChangesinNumberofOtherEquityInstrumentsOutstandingDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements", "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r93", "r184" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax losses carry forwards - US", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r377" ] }, "inpha_UnrealizedGainsOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UnrealizedGainsOnFinancialAssets", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on financials assets", "label": "Unrealized Gains On Financial Assets", "documentation": "The amount of unrealized gains on financial assets." } } }, "auth_ref": [] }, "inpha_UnrealizedLossesOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UnrealizedLossesOnFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized losses on financial assets", "label": "Unrealized Losses On Financial Assets", "documentation": "The amount of unrealized losses on financial assets." } } }, "auth_ref": [] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax losses carryforwards", "label": "Unused tax losses [member]" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r6", "r156" ] }, "inpha_UnusedTaxLossesSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UnusedTaxLossesSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused tax losses subject to expiration", "label": "Unused Tax Losses Subject To Expiration", "documentation": "The amount of unused tax losses subject to expiration." } } }, "auth_ref": [] }, "inpha_UnusedTaxLossesSubjectToExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UnusedTaxLossesSubjectToExpirationPeriod", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Unused Tax Losses Subject To Expiration, Period", "documentation": "Unused Tax Losses Subject To Expiration, Period" } } }, "auth_ref": [] }, "inpha_UnusedTaxLossesWithNoExpirationDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UnusedTaxLossesWithNoExpirationDate", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncomeTaxAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused tax losses with no expiration date", "label": "Unused Tax Losses With No Expiration Date", "documentation": "The amount of unused tax losses with no expiration date." } } }, "auth_ref": [] }, "inpha_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UpfrontPayment", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Upfront Payment", "documentation": "The upfront payment made to a counter party." } } }, "auth_ref": [] }, "inpha_UpfrontPaymentCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UpfrontPaymentCash", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment, cash", "label": "Upfront Payment Cash", "documentation": "The amount of cash paid for the the upfront payments." } } }, "auth_ref": [] }, "inpha_UpfrontPaymentSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "UpfrontPaymentSharesIssued", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ThecompanyAgreementsrelatedtoavdoralimabwithNovoNordiskandwithAstraZenecaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment, shares issued", "label": "Upfront Payment Shares Issued", "documentation": "The value of shares issued for the upfront payments." } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortisation period, intangible assets other than goodwill", "label": "Useful life measured as period of time, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r36", "r173" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.innate-pharma.com/role/AccountingpoliciesandstatementofcomplianceDisclosureofDepreciationPeriodsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation period, property, plant and equipment", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r8", "r157" ] }, "inpha_VestingPeriodOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "VestingPeriodOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofClosingBalanceofShareBasedPaymentArrangementsDetails", "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofTermsandConditionsofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vesting period (years)", "terseLabel": "Vesting period (years)", "label": "Vesting Period Other Equity Instruments Granted", "documentation": "The vesting period of other equity instruments granted." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r346" ] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r413" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.innate-pharma.com/role/SharecapitalandsharebasedpaymentsDisclosureofNumberandWeightedAverageExercisePricesofOtherEquityInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share)", "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r421" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareSummaryofIncomeLossperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of ordinary shares in circulation (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r32" ] }, "inpha_WithholdingRateCIR": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "WithholdingRateCIR", "presentation": [ "http://www.innate-pharma.com/role/ConsolidatedStatementofCashFlowsParenthetical", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding rate realized by CIR", "label": "Withholding Rate , CIR", "documentation": "Withholding Rate , CIR" } } }, "auth_ref": [] }, "inpha_WithholdingTaxCIRReclassifiedUnderNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "WithholdingTaxCIRReclassifiedUnderNonCurrentFinancialAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding tax - CIR reclassified under non-current financial assets", "label": "Withholding Tax - CIR Reclassified Under Non-Current Financial Assets", "documentation": "Withholding Tax - CIR Reclassified Under Non-Current Financial Assets" } } }, "auth_ref": [] }, "inpha_WriteOffOfALeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "WriteOffOfALeaseLiability", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write-off of a lease liability", "label": "Write-Off of a Lease Liability", "documentation": "Write-Off of a Lease Liability" } } }, "auth_ref": [] }, "inpha_WriteOffOfARightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20251231", "localname": "WriteOffOfARightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write-off of a right-of-use asset", "label": "Write-Off of a Right-Of-Use Asset", "documentation": "Write-Off of a Right-Of-Use Asset" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r344" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_g&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_v&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B51&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "105", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_b&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "178", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "203", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_203&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_f&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "216", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_216_a&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_v&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_b&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_b&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_g&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_d&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r341": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r342": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r343": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r344": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r346": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r347": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r348": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r349": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r350": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r351": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r352": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r353": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r354": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r356": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r357": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r358": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r359": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r360": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r361": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r362": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r363": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r364": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r365": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r366": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r367": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r368": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r369": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r370": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r371": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r372": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r373": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r374": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r375": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r376": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r377": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r378": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r379": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r380": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r381": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r382": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r383": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r384": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r385": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r386": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r387": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r388": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r389": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r390": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r391": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r392": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r393": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r394": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r395": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r396": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r397": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80&doctype=Standard", "URIDate": "2025-03-27" }, "r403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141&doctype=Standard", "URIDate": "2025-03-27" }, "r408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2025-03-27" }, "r410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2025-03-27" }, "r411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }